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CONDENSED ABSTRACT 
 
The Scientific Council and the Working Group on Hypertension in Children and Adolescents of 
the ESH acknowledged the importance of diagnosis, management and treatment of high BP in 
this age group and recognised the need for an update of the 2009 guidelines because over the 
seven years elapsed from their publication a large body of new knowledge had been acquired, 
making, modifications and expansion of the previous recommendations necessary. 
It is hoped the new knowledge summarised in these Guidelines will lead to increased efforts 
towards prevention and management of HTN in the pediatric age, thus also helping relieving 
the burden of cardiovascular disease in adults. 
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1. INTRODUCTION AND PURPOSE  
1.1 Purpose 
The European Society of Hypertension (ESH) Guidelines on  High Blood Pressure in Children 
and Adolescents published in 2009 (1) were undertaken  because of growing evidence  that  
mild blood pressure (BP) elevations are much more common among children and adolescents 
than previously thought; and  BP abnormalities in youth frequently translate into adult 
hypertension (HTN), what is known as the tracking phenomenon. 
The Scientific Council and the Working Group on Hypertension in Children and Adolescents of 
the ESH (ESH) acknowledged the importance of diagnosis, management and treatment of high 
BP in this age group and recognised the need for an update of the 2009 guidelines because 
over the seven years elapsed from their publication a large body of new knowledge had been 
acquired, making, modifications and expansion of the previous recommendations necessary. 
It is hoped the new knowledge summarised in these Guidelines will lead to increased efforts 
towards prevention and management of HTN in the pediatric age, thus also helping relieving 
the burden of cardiovascular (CV) disease in adults. 
 
1.2 What is new? 
Increasing prevalence of HTN in children and adolescents has become a significant public 
health issue driving a considerable amount of research. Aspects discussed in this document 
include advances in the definition of HTN in 16 year or older, clinical significance of isolated 
systolic hypertension (ISH) in youth, the importance of out of office and central BP 
measurement, new risk factors for HTN, methods to assess vascular phenotypes, clustering of 
CV risk factors, and treatment strategies among others. 
 
1.3 How the document has been prepared 
The European members in charge of the 2016 guidelines were appointed by the ESH Council, 
on the basis of their recognized interest and experience in the area. Each member was 
assigned a specific writing task according to their expertise, and  each contribution was 
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reviewed by all the co-authors. The text was finalized over approximately 12 months, during 
which the members corresponded intensively. It can thus be confidently stated that the 
recommendations issued by the 2016 ESH guidelines largely reflect the state of the art on HTN, 
as viewed by pediatricians and hypertension experts in Europe.  
The document has 14 sections which contain 19 Tables, 4 Figures and 6 Boxes who summarize 
the most relevant recommendations providing an easy access to the readers.  Data upon which 
recommendations are based are  referenced at the end of the document. 
 
1.4. How to detect hypertension in children: pros and cons of screening 
The early recognition of BP abnormalities is crucial if there are to be early interventions that 
may reduce CV morbidity and mortality later in life. Current guidelines clearly state that a child 
should not be diagnosed with HTN until he or she has shown evidence of sustained BP 
elevation (1). Several prominent medical organizations, including the National High Blood 
Pressure Education Program, the American Academy of Pediatrics and the American Heart 
Association recommend routine measurement of BP in children and adolescents. However, 
these recommendations are not deeply grounded and controversy has been raised about 
benefits and costs of routine screening (2,3). In 2013, the US Preventive Services Task Force 
concluded that the “current evidence is insufficient to assess the balance of benefits and 
harms of screening for primary hypertension in asymptomatic children and adolescents to 
prevent subsequent CV disease in childhood or adulthood” (2).  The pros and cons of screening 
have been widely debated, recently (4-6). The group responsible for these guidelines has 
considered that lack of evidence does not necessarily justify inaction; that opportunistic BP 
screening in children is associated with minimal cost and time inputs, and does not include 
invasive and expensive tests. It may also lead to further actions improving health outcomes (3). 
Therefore, the consensus of the present Guidelines is that BP should be measured in children 
starting from age 3 years. Once BP is measured, children considered normotensive should be 
re-evaluated every two years, whereas those with high-normal BP and no organ damage 
should be seen again after one year. This recommendation was already given in the 2009 
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Guidelines here reconfirmed. Also reconfirmed is the advice that, once a diagnosis of HTN has 
been established, children should be referred to units with expertise in managing this 
condition in the pediatric age. 
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2. DEFINITION AND CLASSIFICATION OF HYPERTENSION  
2.1 Classification of hypertension 
On the contrary to what happens for adults, the definition of HTN in children is arbitrary, and is 
based on the normal distribution of BP in healthy children and not on the CV morbidity and 
mortality associated with a certain level of BP. Diagnostic criteria for elevated BP in children 
are based on the concept that BP in children increases with age and body size, making it 
impossible to utilize a single BP level to define hypertension, as done in adults.  Because of the 
persisting lack of European reference values that incorporate age, sex and height, throughout 
the entire pediatric age range, we confirm the decision of the 2009 ESH Guidelines (1), to use 
the normative data on auscultatory clinic measurements provided by the US Task Force (7), 
providing BP percentiles for each sex, ages from 1-17 years and for seven height percentile 
categories.   
As in the previous guidelines, hypertension in children is defined as systolic BP (SBP) and/or 
diastolic BP (DBP) persistently ≥95th percentile for sex, age and height measured on at least 
three separate occasions, as outlined  in the Figure 2.1.1. Children with average SBP and/or 
DBP ≥90th, but <95th are classified as having high-normal BP. In the present document, the 
definitions have been revised for older adolescents. Considering the 95th percentile for age, sex 
and height as the definition of HTN, a 16 year old boy in the 95th percentile for height would be 
defined as hypertensive by an office SBP of 137-140 mmHg, while a 16 year old girl in the same 
height percentile by an office SBP of only 132 mmHg. One-two years later, no longer seen by a 
pediatrician, the girl will now be diagnosed as normotensive or high normal by the family 
physician on the basis of adult guidelines. Even greater differences in diagnosis will occur in 
adolescents shorter than the 95th height percentile. Due to these differences in diagnosis, a 
consensus in the present Guidelines is given that for boys and girls aged 16 or older, the 
definition of HTN should no longer be based on the 95th percentile but on the absolute cut-off 
used for adults, which defines high-normal (130-139/85-89 mmHg) and HTN (≥140/90 mmHg) ( 
Fig. 2.1.1 and Table 2.1.1). 
8 
 
In addition, HTN is further classified as grade 1 (95th percentile to the 99th percentile plus 5 
mmHg) and grade 2 (>99th percentile plus 5 mmHg). In the case of subjects 16 years or older 
hypertension should be graded as for adults. Tables 2.1.2 and 2.1.3 report the BP percentiles 
for boys and girls, aged 1-15 years, adapted from the Fourth Report of the US Task Force (7). 
 
2.2 Systolic versus diastolic  
Elasticity of the great vessels is particularly relevant in youth, and causes SBP to be 
considerably higher in upper limb arteries than in the ascending aorta, increasing the presence 
of so-called ISH. This condition in youth is defined as SBP ≥95th percentile specific for sex, age 
and height, with DBP <90th percentile (8). In 16 years and older SBP ≥140 mmHg and DBP <90 
mmHg, see Table 2.1.1. The clinical significance of ISH in youth is still debated, as discussed in 
section 1.4.5.   
 
2.3 Risk of hypertension in adult life  
Previous studies have demonstrated that elevated BP in childhood is the strongest predictor of 
HTN in the adult and the increment of risk of HTN in adult life results from adolescents in the 
highest BP percentiles (9-12). Increments in SBP of 15 mmHg or 30 mmHg above 90 mmHg in 
15-year olds, represent probabilities of having HTN at 35 years of 0.18 and 0.33 respectively 
for boys. These probabilities are lower for girls, 0.04 and 0.08, respectively, with 4.25 more risk 
for boys than for girls (13). In a longitudinal study, BP at adolescence, even in the low-
normotensive range linearly predicted progression to HTN in young adulthood (11). This 
progression was shown to be sex-dependent, and was 3- to 4-times higher among men than 
women in all BP categories.  
Blood pressure values in adolescence can also be predictors of CV risk other than HTN. After 17 
years of follow-up, BP values in young individuals show a significant association with 
cardiometabolic risk (14), and may also predict coronary artery disease in adult life (15). 
Likewise, BP values at adolescence are independent predictors of End Stage Renal Disease 
(ESRD) in middle-aged men (16).   
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2.4 Relative cardiovascular and renal risk  
Hypertension impacts on the heart, kidney, central nervous system and vessels producing early 
functional or structural changes that can be detected by using appropriate assessment 
methods.  Among children and adolescents with primary HTN, 30-40% had a left ventricular 
mass index (LVMi) above the 95th percentile and 10-15% of them had severe left ventricular 
hypertrophy (LVH) defined as LVMi above 51g/height2.7 (17- 19). Renal damage is rarely 
observed in essential hypertensive children, but these subjects have greater albuminuria and 
excrete more N-acetyl glicosamine than their normotensive counterparts. The severity of 
albuminuria correlates with LVH (20,21). On the other hand antihypertensive treatment when 
successful in reducing BP, also leads to regression of LVH, decrease in carotid intima-media 
thickness (cIMT) and normalization of microalbuminuria (22-24). Likewise, in children with 
chronic kidney disease (CKD) proteinuria correlates with BP, and strict BP control leads to a 
decrease in proteinuria and a slowing of the progression of CKD (25). Therefore, assessment of 
early organ damage, as a measurement of the clinical consequences of increased BP, is 
essential for HTN management in youth (see section 4.7). 
 Monitoring organ damage in children and adolescents with elevated BP is even more 
important as the CV/renal sequelae of childhood-onset HTN may not become clinically 
relevant before adulthood. Prospective studies have shown that elevated BP in adolescence is 
associated with both subclinical dysfunction of the left ventricle in the fifth decade of life and 
increased arterial stiffness (26-29). Similarly, young adults with greater pulse wave velocity 
(PWV) had steeper increases of BP and visceral obesity from the age of 13 years (30).  
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3. EPIDEMIOLOGY   
3.1 Prevalence  
Because  the definition of HTN in children is based on BP values greater that the 95th percentile 
in normal healthy individuals, the prevalence of HTN should be around 5%. This rarely 
happens, however, probably because the normative values used are limited to the USA and 
may not exactly apply to other part of the world, or because the normative data are more than 
twenty years old and the current epidemics of overweight and obesity may have changed the 
matter. Furthermore, despite the number of studies that have been performed, the 
prevalence of pediatric HTN worldwide is  difficult to establish also because of the regional 
differences in the definition, the distribution of reference BP data, and the methods of BP 
measurement. Central-European studies showed the prevalence of HTN in adolescents to be 
2.2% in Switzerland, 2.5% in Hungary and 4.9% in Poland (31-33). Data from Southern Europe 
identified higher prevalence; adolescent HTN was estimated as 9% in Turkey, 12% in Greece 
and 13% in Portugal (34-36). After the age of 10, primary HTN is the predominant form (37) 
and in the majority of the adolescent hypertensives, 81% were ISH (31). For European 
prevalence see Table 3.1.1.  
The obesity epidemic in children and adolescents makes it plausible that prevalence rates of 
HTN are increasing over time (38).  HTN was found in 1.4% of normal weight, 7.1% of 
overweight and 25% of obese adolescents (39). The relative risk of HTN for overweight 
subjects is 3.26 (CI: 2.5-4.2) (40) and based on a multiple regression model - besides gender - 
BMI is the strongest determining factor of adolescent blood pressure (32). A recent study 
reported the prevalence of HTN in overweight or obese 6-18 year old subjects, to range 
between 27 and 47%, according to different reference values (41). 
 
3.2 Incidence  
Reports on incidence of HTN in childhood are mainly concerned with progression  from high-
normal BP to HTN among adolescents and on the incidence of HTN in children from  groups at 
risk of CV disease, such as masked HTN, type 2 diabetes mellitus (DM2), obesity or  repaired  
11 
 
aortic coarctation (CoA). In a general population of adolescents, 10-19 years, the rate of 
progression from normotension to HTN was 0.4/100 subjects/year, and among those who had  
high-normal BP it was 1.1/100 subjects/year (42). In another study on normotensive children 
with a mean follow-up of 35 months, the incidence of sustained HTN was 0.6/100 
subjects/year (43). In the same study, masked hypertensive subjects had an incidence of 
sustained HTN of 7/100 subjects/year, the risk being higher in boys than in girls (43). The 
incidence in adolescents with T2D was estimated as 4/100 subjects/year (44). Obese children 
aged 3 to 11 had a two-fold increased risk of developing HTN than normal weight children, 
while those with severe obesity had a more than four-fold increased risk (45). After successful 
repair of CoA, the incidence rate was found to be 1.3/100 subjects/year (46).   
 
3.3 Family aggregation and Genetics  
There is extensive evidence from family studies that BP is moderately heritable with 15-40% of 
office SBP and 15-30% of office DBP explained by variation in genetic factors (47). Ambulatory 
BP appears more heritable with 69% and 51% for the ambulatory night-time systolic and DBP, 
respectively (48). A recent analysis of BP heritability in families of the Gubbio population 
followed-up for 25 years shows that also the SBP/DBP variation with aging has a genetic 
component (33-43% for SBP, 24-25% for DBP), with a much smaller component (4-17%) due to 
shared environment (49). These findings suggest that BP is a complex, polygenic trait with no 
single gene exerting a predominant effect on the trait. However, we are also aware of several 
rare syndromes with classic Mendelian inheritance, which present with very high or low BP 
early in life (50). The discovery of genes responsible for these monogenic syndromes has 
highlighted the importance of the kidneys and the adrenal glands in BP regulation as well as 
indicating efficacious treatments driven by the understanding of molecular pathophysiology of 
each of these rare syndromes. Furthermore, family screening is now available in national 
reference laboratories. In summary, HTN is a polygenic trait with the rare syndromes 
representing the extreme end of the BP distribution (51). 
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3.4. Ethnic minorities  
Childhood BP, particularly ambulatory BP measurement (ABPM), remains seriously 
understudied in “ethnic minorities” (EM), meaning descendants of non-‘Europeans’, generally 
South Asian, sub-Saharan African or African-Caribbean by origin in Europe, as well as among 
refugee children (52).  Despite the lack of direct evidence, the latter are likely to have higher or 
potentially much higher BP values. Without evidence, the standard guidelines have to apply to 
EM children, with safeguards for generational time since (parental) migration. Ethnic minority 
children may well have been born smaller, possibly from more frequent hypertensive/pre-
eclamptic pregnancies, so at greater CV risk themselves.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. DIAGNOSTIC EVALUATION  
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4.1 Blood pressure measurement  
Office BP measurement has provided the basis for the present knowledge of the potential risk 
associated with HTN and has guided patient management for many years. Although office BP 
should be used as a reference, BP values obtained out-of-office may improve the evaluation in 
untreated and treated subjects. Additionally, in the last years, the assessment of central BP has 
been introduced. 
 
4.1.1 Office blood pressure  
The main issue about how to measure BP in children is whether to use the auscultatory or the 
oscillometric method.  In the auscultatory method, Korotkoff sounds are used to assess SBP 
(K1) and DBP (K5) while deflating the cuff (1). Oscillometric devices measure mean BP directly 
from the point of maximum oscillation; neither SBP nor DBP are measured directly, but are 
calculated using an algorithm based on a putative relationship between the oscillations. If an 
oscillometric method is applied, the monitor should have passed the validation procedure 
recommended by the British Hypertension Society (53), the American Association for the 
Advancement of Medical Instrumentation (54) or the ESH International Protocol (55). Few 
oscillometric devices for office, home or ambulatory BP monitoring have been successfully 
validated using an established protocol in children.  Continuously updated information on 
monitor validation for children is found at www.dableducational.org. It should be noted, 
however, that available reference values for defining BP categories (See tables 2.1.2 and 2.1.3) 
have been obtained by the auscultatory method. Values obtained with oscillometric 
equipment are considerably higher than the auscultatory ones. Therefore if HTN is detected by 
the oscillometric method, it must be confirmed by the auscultatory one.  After the 
recommendations of the 2009 ESH Guidelines, recent studies have been conducted to develop 
reference values using oscillometric devices (56-58). Unfortunately the heterogeneity of the 
studies does not allow pooling of  the information.  The specific recommendations for office BP 
measurement in children and adolescents are shown in Box 1.  
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4.1.2 Ambulatory blood pressure  
Ambulatory BP measurement is now increasingly recognized as  providing extremely useful 
information for the diagnosis and management of HTN and  has contributed significantly to our 
understanding of HTN by "unmasking" BP phenomena that were not readily apparent using 
office BP. Blood pressure measurement in the more meaningful context of daily real-life 
conditions, not just in the artificial environment of the physician’s office and clinic, has allowed 
much more in-depth investigation of BP. Values obtained using 24-hour ABPM have  some 
better relationship with the presence of organ damage and a higher reproducibility than those 
obtained using office BP (59).  
Average daytime and night-time BP can be calculated on the basis of the reported times of 
getting up and going to bed, or using fixed time periods (daytime from 8am to 10 pm, night-
time from midnight to 6 am), in which the rising and retiring periods—which differ from  
individual to  individual —are eliminated. For recommended methodology, the reader is 
referred to the Guidelines of Ambulatory BP measurement of the ESH (60). 
A positive correlation exists between ambulatory and office BP for both systolic and DBP in 
normotensive children, even though ambulatory BP values are generally higher than their 
office BP counterparts. The higher ambulatory BP in normotensive children is reversed when 
monitoring hypertensives (61), a behaviour similar to that observed in the adult population, in 
which the difference between office and ambulatory BP gradually diminishes the lower is 
office BP, until for SBP values of about 120 mmHg also in adults ambulatory becomes higher 
than office BP (61.62).  While the higher ambulatory than office BP in normotensive children 
has been attributed, at least in part, to physical activity, additional reasons may reside in the 
different method of measuring BP (61), the algorithm used to calculate systolic and DBP from 
the maximal amplitude (63), and the phenomenon of regression to the mean (61). 
The clinical interpretation of 24-hour ABPM depends on the use of normal BP ranges as 
reference values.  These have now been obtained from different European populations (Tables 
4.1.2.1, 4.1.2.2, 4.1.2.3 and 4.1.2.4) but were not obtained in parallel with the office BP values 
available, since they come from different populations, countries and years. Based on the 
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arguments discussed in section 2.1 on Classification of Hypertension, the consensus of the 
present Guidelines is that the 95th percentile can be used as a threshold for HTN in children 
and adolescents as long as the values are inferior to the accepted criteria for adults (24-hour 
130/80 mmHg; daytime 135/85 mmHg, nightime 125/75 mmHg).  
The night-to-day BP ratio represents circadian variability due to the physiological nocturnal BP 
fall. Blood pressure normally decreases during the night—defined as ‘dipping’. Although the 
degree of night-time dipping has a normal distribution in a population setting, it is generally 
agreed that the finding of a nocturnal BP fall of >10% of daytime values (night-day BP ratio 
<0.9) can be accepted as an arbitrary cut-off to define subjects as ‘dippers’, although one 
should bear in mind that the reproducibility of the dipping pattern is limited. Possible reasons 
for absence of dipping are sleep disturbance, obstructive sleep apnoea, obesity, high salt 
intake in salt-sensitive subjects, orthostatic hypotension, autonomic dysfunction, CKD and 
diabetes, both type 1 and type 2. 
Recommendations for the use of 24-hour ABPM are given in Box 2. They include 
measurements made with the purpose of diagnosis, evaluation during treatment as well as in 
clinical trials and other conditions, in which the presence of orthostatism or rapid and episodic 
elevation of BP are difficult to detect in the office.   Especially in children, 24-hour ABPM 
should be recommended before starting antihypertensive treatment, in order to avoid treating 
with drugs children with “white-coat” HTN. 
 
4.1.3 Home blood pressure  
Feasibility of home BP monitoring in children and adolescents has been reported in different 
ethnic populations (64-66) Home BP correlates closely with daytime ambulatory BP values and 
has superior reproducibility to office BP, similar to that of ABPM (67). Home BP is lower than 
daytime ambulatory BP in children and adolescents (65, 68-70). Some preliminary evidence 
exists that home BP in children correlates with target organ damage (TOD) better than office 
BP (71), and that it may also better reflect the effect of risk factors on BP, such as family 
history or obesity (66, 72-73). Two research groups reported good performance of home BP to 
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diagnose white-coat HTN, but a low sensitivity and positive predictive value to predict masked 
HTN compared to ABPM (68,74). Methodological aspects and recommendations for use of 
home BP are shown in Box 3. Home BP monitoring for 6-7 days, with duplicate morning and 
evening measurements is recommended, as most available studies in children used a schedule 
of at least 6 day -monitoring. A 3-day monitoring was found to be the minimum reliable 
schedule against 6 day-readings (75).  
One school-based study provided the only normalcy data for home BP in children and 
adolescents (Table 4.1.3.1) (64). The criteria to define HTN based on home BP is BP being 
higher than or equal to 95th percentile for sex and height, as long as the values are inferior to 
the criteria accepted for adults (average 135/85 mmHg). Several issues about the clinical 
application of the method, including validated devices, remain under-investigated.   
 
4.1.4 White-coat and masked hypertension 
White-coat HTN is defined as elevated BP in office, yet normal  being elsewhere. The reported 
frequency of white-coat HTN varies, perhaps as a result of the criteria used to establish the 
diagnosis, ranging from 1% to 44% (76). At present, no long-term follow-up data are available 
for children with white-coat HTN at initial assessment, in order to know the reproducibility and 
the real impact of this condition. Hence, it remains to be clarified whether white-coat HTN is 
an innocuous phenomenon or a prelude to future sustained HTN. 
The inverse phenomenon, masked HTN, defined as normal BP in the office but elevated BP 
outside the office, occurs in approximately 10% of children and adolescents (74, 77-80). The 
persistence and clinical significance of the phenomenon has shown that in 40% of children, the 
abnormal elevation of the daytime ambulatory BP persisted over a minimum of 6 months (79). 
Masked HTN has been linked with progression to HTN in youth, with the risk being higher in 
boys than in girls (43). Masked HTN warrants follow-up, and if it persists, left ventricular mass 
(LVM) should be assessed.  
 
4.1.5 Central blood pressure  
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Mean and DBP are nearly constant throughout the arterial tree, but SBP varies, with peripheral 
higher than central or aortic (cSBP) (81). Compared with adults, this phenomenon differs 
significantly in children, whose SBP amplification is substantial, a mean ~20 mmHg, almost 
twice  as in adults (82). If cSBP relates more closely than peripheral SBP to TOD, including LVH, 
as some claim in adults (83), it may be very useful clinically to estimate its values in children, 
but its benefit and independence from peripheral BP remains unknown. The recent publication 
of percentiles for cBP in children and adolescents, specific for sex and age or height, has the 
potential for widespread clinical use and may provide additional information about vascular 
phenotype (84), if the method is correctly validated in children.  Although a range of devices 
are now available to estimate cBP using different noninvasive techniques in adults, but we 
need further data on agreement between these various devices.  
The potential value of cSBP and central pulse pressure (cPP) in the assessment of adolescents 
with ISH, is a controversial issue. cBP may be especially relevant in asymptomatic children 
incidentally found to have isolated peripheral systolic HTN without TOD. In children and young 
adults at high risk of future adverse CV outcomes (e.g. with essential HTN or CKD), research is 
needed on what factors determine systolic amplification as well as interventions that have 
differential impact on central rather than peripheral systolic pressure. Because of their high 
correlation, cBP will only offer incremental value over peripheral BP if cBP identifies TOD 
better. 
 
4.1.6 Blood pressure during exercise  
The BP response during physical exercise has been suggested for that diagnostic assessment of 
BP in children. Longitudinal studies have shown that SBP or the calculated heart rate and SBP 
product during exercise are positively associated with future resting BP, even independent of 
resting SBP and other CV risk factors (85,86). An exaggerated BP response to treadmill exercise 
has been observed in children with white-coat HTN (87). Likewise, an exaggerated SBP during 
exercise has also been reported in children at risk for early damage in vascular structure and 
functioning (88-90). In order to establish the clinical usefulness of BP response to exercise 
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testing in children and adolescents with HTN, a larger body of data is needed.  Even though 
reference values for SBP during exercise are now available, they are restricted to the age range 
12-16 years (91). The ESH Guidelines in adults suggest performing 24-hour ABPM in subjects 
with a hypertensive response during the treadmill test searching for the possible presence of 
masked HTN (92). Even though evidence in youth is lacking, this recommendation can be 
applied in adolescents.  
 
4.2. Family and clinical history  
Family and clinical history should precede further diagnostic evaluation of HTN in children and 
adolescents to allow a targeted individualized approach and avoid inappropriate, expensive 
and invasive tests. Family history of HTN or CV disease may identify children and adolescents 
with essential HTN, but history of hereditary diseases associated with secondary forms of HTN 
should also be relevant (1,37). Parental history of HTN has been associated with masked HTN, 
early TOD, changes in central and peripheral hemodynamics, and can guide further evaluation 
(79,93-95). A complete clinical history assessment may include information summaraised in 
Table 4.2.1. 
 
4.3. Birth weight  
The importance of intrauterine and early life events in development  of cardiometabolic 
disease  in adult life has been  underlined (96-100). The time immediately before and after 
birth may be a sensitive period in which multiple interactions between hemodynamic and 
metabolic parameters foreshadow the clustering of cardiometabolic risk factors later in life 
(101,102). A critical window of opportunity to modify programming may exist during 
pregnancy and throughout the first years of life when strategies aiming to reduce risk can be 
implemented. This is an expanding area for promising further investigation. 
 
4.4. Physical examination 
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All children identified as having HTN should have their height and weight measured and 
classified by percentiles. Other than the findings of HTN itself and obesity, physical 
examination in children with HTN is frequently entirely normal. Nevertheless, a careful 
examination is mandatory to identify features of disorders that may be the cause of secondary 
HTN as well as identifying evidence of end-organ damage. See Table 4.4.1. 
 
4.5. Laboratory investigation  
Routine laboratory tests and imaging studies must be performed in all children with HTN. 
Other additional tests are necessary in specific conditions. See Table 4.5.1. 
 
4.6. Genetic analysis  
Genetic analysis merits a specific comment even if it has not yet been demonstrated to have a 
clear role to play in the routine assessment of children with HTN.  
The human genome project in 2001 led the way to large-scale genomic studies in populations. 
The current list of known variants contributing to genetic architecture of BP and HTN includes 
more than 25 rare mutations and 53 single nucleotide polymorphisms (SNPs) as recently 
reviewed (51). It is now possible to use whole genome DNA sequencing or exome sequencing 
to diagnose rare monogenic syndromes although more traditional single gene PCR-based tests 
are also used successfully. 
Monogenic causes of HTN are rare, but they should be detected during the pediatric age, for 
successful treatment and avoidance of the HTN associated morbidity and mortality. The 
monogenic HTN syndromes are good examples of perfect pharmacogenetic, where the 
knowledge of the functional genetic mutation allows for targeted therapy. All presently known 
monogenic causes of HTN are characterized by abnormal sodium transport in the kidney, 
volume expansion and low renin. Among them, Liddle’s syndrome, glucocorticoid-remediable 
aldosteronism, apparent mineralocorticoid excess, Gordon’s syndrome, mineralocorticoid 
receptor hypersensitivity syndrome and hypertensive forms of congenital adrenal hyperplasia 
have been identified (1). Monogenic diseases should be suspected in children with low renin 
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HTN and a family history of early-onset severe HTN, death from cerebral vascular accidents 
and heart failure or refractory HTN. Hypokalemia is a common feature of the majority of low 
renin HTN stated with the exception of Gordon’s syndrome.  
 
4.7. Searching for target organ damage  
Once HTN is confirmed, organ damage evaluation should be assessed due to the importance of 
subclinical organ damage as an intermediate stage in the continuum of vascular disease. 
Subsequently, evaluation of organ damage is also useful as an intermediate endpoint for 
monitoring treatment. A summary of the criteria to define HTN-induced organ damage can be 
found in Table 4.7.1. 
 
4.7.1. Heart  
Assessment of LVM and geometry remain a cornerstone when looking for end-organ damage 
in sustained pediatric HTN (17,103). Following the Joint European Association of 
Echocardiography and American Society of Echocardiography (104), LVM should be calculated 
using the cube formula (105) and indexed (LVMI) by height2.7 (106). Traditionally left 
ventricular hypertrophy (LVH) has been defined as LVMI or relative wall thickness (RWT) ≥ 95th 
percentile by age and gender (107,108). A recent paper by Chinali and Co-workers suggest to 
use a simplified approach for the identification of LVH in infants, children and adolescents with 
a single partition value across the whole age range (109). Using LVM/[height]2.16 a single 
partition value of 45 g/m2.16 and validated against a cohort of 130 healthy subjects, no false 
positives for LVH were found. 
The ratio of Doppler transmitral flow (E) and tissue Doppler derived early diastolic velocity (E´), 
reflecting diastolic function, independently predicts primary cardiac events in hypertensive 
adults (110). Reference values of E/E´ are poorly defined in children and adolescents. 
Nevertheless, if technically available, it is recommended to include it in the longitudinal follow-
up of individual patients and it most certainly should be included in future echocardiographic 
study protocols of hypertensive children and adolescents. A 12-lead ECG adds little to early 
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detection of cardiac end-organ damage (LVH) due to its overall poor reliability in children 
(111,112). 
 
4.7.2. Blood vessels  
Improved imaging methods (high definition ultrasound and echotracking) have enhanced 
‘reference’ values for cIMT and arterial distensibility in healthy children aged 3-18 years 
(113,114). Carotid intima media thickness and distensibility, associated with age, 
anthropometry and BP are elevated in at-risk children with familial hypercholesterolaemia 
(115,116), overweight (117,118), HTN (119,120), and type 1 diabetes (121).  
Arterial stiffening measured by PWV predicts CV events and mortality in adults (122). 
Reference values for PWV are now available from three studies that have been performed in 
childhood (84,123,124). Overall, current data suggest childhood BP only variably predicts 
increased PWV (125-127). Emerging data suggest that functional changes in large vessels are 
the earliest detectable findings in children, for example in those with familial 
hypercholestrolaemia and CKD (128,129). 
Routine assessment of arterial stiffness and central BP parameters are not currently 
recommended and they should be maintained as a research area until further information is 
available.  
 
4.7.3. Kidney  
High BP itself may affect kidney function by inducing albuminuria (albumin/creatinine quotient 
>30mg/g creatinine or >3mg/mmol creatinine) or even proteinuria (>300mg/g creatinine or 
>30mg/mmol creatinine or 200 mg/m²/day) (130). Hematuria, proteinuria and edema 
formation indicate glomerular damage, but also failure to thrive, polyuria and polydipsia are 
symptoms of renal disease.  
Full blood count, plasma sodium, potassium and calcium, urea, creatinine, uric acid and 
urinalysis (hematuria, proteinuria, leukocyturia) plus quantitative measurement of albuminuria 
and proteinuria should be performed in all children with HTN (1,7). Reduced glomerular 
22 
 
filtration rate (GFR in ml/min per 1.73m²) should be estimated according to Schwartz formula 
and permanently (>3 months) reduced estimated GFR indicates renal damage. 
Renal imaging by renal ultrasound is required in every child with HTN to exclude Wilms tumor, 
neuroblastoma and renal cystic diseases or dysplasia. Reduced renal perfusion by renal artery 
stenosis or by mid aortic stenosis increases BP and can be detected by renal Doppler 
ultrasound, magnetic resonance tomography or direct renal angiography, the gold standard 
(131).     
 
4.7.4. Fundoscopy  
Data on incidence, findings and prognosis of hypertensive retinopathy (HTNR) in children are 
scarce (132). American children with essential HTN had HTNR based on arteriolar narrowing in 
fundus photographs and fluorescein angiography in 51% of 97 children (133). This was not the 
case when HTNR was examined by an ophthalmologist and assessed by dilated 
ophthalmoscopy; only 3/35 (8.6%) had mild HTNR (134). In a British sample, 7/39 children 
(18%) had HTNR, 6 with severe disease (hemorrhages, exudates, disc edema), some with 
permanent visual reduction (135). Fundoscopy should likely be limited to children with 
symptoms, encephalopathy or malignant HTN. 
 
4.7.5. Brain  
Sustained and severe high BP may affect the brain by various symptoms and signs (cerebral 
seizures, stroke, visual impairment and retinal vascular changes) (136). Then, neurologic 
clinical evaluation and diagnostic procedures, e.g. electroencephalography, ultrasonography 
during infant age, and by cranial computed tomography (CT), to exclude intracranial 
haemorrhage, need to be performed. Severe acute HTN causes a hypertensive emergency with 
specific symptoms (headache, visual impairment, dizziness, impaired consciousness, seizures 
or neurological deficits, e.g. facial nerve paresis). In these cases Magnetic Resonance Image 
(MRI) is required, which is able to identify small silent brain infarcts, microbleeds, white matter 
lesions and posterior reversible encephalopathy syndrome (PRES) (137). 
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4.8. Biomarkers  
Biomarkers could be considered as tools to stratify the risk of patients at an individual level 
and/or to serve as surrogate endpoints of CV events (138). 
A biomarker should be tested against stringent criteria including a proof of concept, prospective 
validation, incremental value, clinical utility, clinical outcomes, cost-effectiveness and reference 
values (139). Biomarkers which fulfill most of the above criteria currently are not available 
today.   
The most likely scenario is that the emerging disruptive technologies such as genomics, 
proteomics and metabolomics would change the way we use biomarkers. Instead of a search for 
one perfect biomarker, we would rely on hundreds or even thousands of molecular markers 
considered jointly to pave the way for the development of precision medicine (140). 
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5. COMORBIDITIES  
5.1. Obesity and Metabolic Syndrome 
Childhood obesity is the most common nutritional problem in developed and developing 
countries and its prevalence in children has doubled since the mid-1980s (141-143) reaching 
pandemic proportions and increasing not only in prevalence but also in severity. According to 
the WHO, 42 million children under the age of 5 were overweight or obese worldwide in 2013 
(144). The increasing tendency for obesity to appear during childhood and to track into adult 
life, as well as the firmly established relationships between obesity, DM2 and HTN in adults, 
means that obese children appear to be at particularly high risk of becoming diabetic and 
hypertensive as they age (145,146).  
Identifying children most at risk for the development of future hypertensive disease is as 
important as assessing BP’s association with other cardiometabolic risk factors. A process of 
clustering may occur when high BP acts together with one or more cardiometabolic risk 
factors, hyperinsulinemia and lipid abnormalities, producing TOD and cardiometabolic disease 
(6). Although the clustering in adults has been labelled as ‘the metabolic syndrome’, a 
consensus definition has been difficult to reach also for the pediatric population. Several 
definitions of metabolic syndrome have been proposed using not only different parameters 
but also different cut-offs. Moreover, as insulin resistance, the major driver of metabolic 
syndrome, is influenced by pubertal stage, it is questionable to use definitions that do not take 
into account pubertal status in pediatric age. As a consequence a widely variable prevalence of 
between 6% and 39% has been reported. High normal BP and HTN are frequently associated 
with one or more cardiometabolic risk factors (147). Therefore, lifestyle changes, particularly 
weight loss and increased physical exercise, are recommended for all individuals. For 
antihypertensive treatment see section 9.4 for specific recommendations.  
 
5.2. Diabetes Mellitus 
In young people, both type 1 diabetes (DM1) and DM2 are increasing in prevalence. The 
correct diagnosis of DM1 and DM2, and monogenic DM is important because it helps to guide 
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therapy, however distinguishing between DM1 and DM2 in children can be difficult since 
autoantibodies and ketoacidosis may be present in patients with features of DM2 (including 
obesity and acanthosis nigricans) (148). Compared with antibody negative, antibody positive 
DM2 are less overweight, have lower BP, better lipid profile, and are more likely to be males 
(149). Youth-onset DM2 occurs at a much greater prevalence in those of non-White European 
descent (Africans, native North Americans, Hispanics, Asians, and Pacific islanders) and in 
Japan, Hong Kong and Taiwan where > 60% of youth-onset diabetes is DM2. In contrast to the 
USA and Europe where nearly all youths with DM2 are overweight/obese, in Asia they are 
often normal weight (149).  
The prevalence of elevated BP is generally higher in youths with DM2 than DM1 (16-36% vs 4-
16%) and reduced nocturnal dipping may also be identified.  Higher BP levels predispose to the 
development of microalbuminuria, nephropathy, HTNR, and carotid thickening and significant 
comorbidities may already be present at the time of DM2 diagnosis (150,151). The 
determinants of BP levels in children with diabetes include poor diet, adiposity, diabetes–
related autonomic imbalance, and poor glucose control (152).  
The Search for Diabetes in Youth Study described the prevalence of elevated BP, awareness, 
treatment, and control in 3691 children with DM1 and 410 with DM2 who attended a visit 
from 2001 to 2010 (150). Compared with youths with DM1, those with DM2 were older and 
more likely female, had an older age at diagnosis, were more likely to be obese (26.5 vs 11.1%) 
and belong to EM (19-76% vs 2.9%). Likewise, they had significantly higher SBP and DBP, lower 
Hb A1C, and higher prevalence of microalbuminuria, despite their shorter duration of DM. The 
percentage of youths receiving BP-lowering medication was very low and children with DM2 
were more likely to receive such treatment. Recent data confirm that HTN is under-diagnosed 
in youths with DM 1 <13 yr of age (153). As a whole, awareness, screening, diagnosis, and 
treatment of elevated BP in youths with DM are not yet satisfactory. 
 
 
26 
 
5.3. Chronic kidney disease and renal insufficiency 
In contrast to adults, where CKD is mainly considered as TOD as a consequence of primary 
HTN, pediatric HTN occurs mostly (in at least 85% of cases) secondarily to an underlying 
renoparenchymal or renovascular disease. The prevalence of HTN in pediatric CKD ranges from 
20 to 80% depending on the degree of renal dysfunction (154-157). However, even children 
with CKD stage 2 (i.e. GFR 60 to 90 ml/min/1.73 m2) may present with elevated BP (158).  
Even though HTN may not be the primary cause of renal disease, BP affects the rate of renal 
failure progression. In adults, HTN is an independent risk factor for CKD progression (159-161) 
and also in a large prospective study of children with CKD SBP greater than 120 mmHg has 
been associated with a faster decline of GFR (162).  
Chronic kidney disease may additionally affect the physiological diurnal variation of BP. The 
integrity of the nocturnal fall of BP (‘dipping’) plays a significant role in renal failure 
progression, in addition to and independent of the absolute BP level. Non-dipping is a well-
known and common characteristic of renal HTN and an independent CV risk factor (163), and is 
associated with faster progression of renal failure in adult CKD patients (164,165).  
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6. EVIDENCE FOR THERAPEUTIC MANAGEMENT OF HYPERTENSION  
6.1. General overview  
Numerous randomized clinical trials in hypertensive adults have provided evidence that 
antihypertensive treatment reduces the risk of death and major CV events such as stroke, 
myocardial infarction, heart failure and renal failure and improves life expectancy (166-170).  
Major CV events are extremely uncommon in childhood, and their rarity has so far prevented 
the running of event-based randomized therapeutic trials. Despite this, clinical experience 
shows that reduction of high BP in life-threatening conditions, such as acute heart failure, 
hypertensive encephalopathy and malignant HTN, improves survival and reduces sequelae in 
children. Because of the rarity of events, most of the limited evidence available so far is based 
on the use of organ damage markers including LVH, urinary albumin excretion, CKD 
progression and increased intima media thickness as endpoints. 
 
6.2. Randomized trials based on intermediate end-points  
6.2.1. Heart 
Antihypertensive treatment results in improved cardiac function and LVH regression, which in 
turn reduces the risk of major CV events in adults (171-173). In children, information on the 
effects of antihypertensive treatment on cardiac end-organ damage is mostly limited to 
uncontrolled studies in heterogeneous populations with primary and secondary HTN. 
Nonetheless, there is pediatric evidence that effective antihypertensive treatment induces 
regression of LVH, ameliorates cardiac geometry and function (22, 23,174-176). In children 
with CKD receiving angiotensin converting enzyme inhibitors (ACEi), improved BP control 
resulted in LVH regression and improved systolic function within 12 months of treatment. 
Lowering BP to the low-normal range, however, resulted in a slightly more marked 
improvement in myocardial function but not in LVMi (175).  
 
6.2.2. Renal function and disease 
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The effects of BP lowering treatment on renal function and disease in adults, especially in 
those with chronic renal disease, are still an area of dispute. A recent meta-analysis (177) has 
concluded for no significant effect on renal failure, but single studies have yielded discordant 
results, which may depend on the different nature of renal disease (e.g., diabetic or 
nondiabetic), presence or absence of proteinuria, and the type of BP-lowering agents (renin-
angiotensin system inhibitors vs other classes). In children, however, the pediatric ESCAPE Trial 
(Effect of Strict Blood Pressure Control and ACE Inhibition on Progression of Chronic Renal 
Failure in Pediatric Patients) demonstrated that superior long-term nephroprotection is 
achieved by targeting for a low-normal 24-hour mean arterial pressure as compared to a high-
normal BP target (25). The partially discrepant findings from experience with adults may be 
explained by methodological and population differences. Patient age, ethnicity, underlying 
renal diseases, pharmacological treatment protocols, duration of follow-up and dropout rates 
varied markedly between the studies. Furthermore, the use of ambulatory BP monitoring in 
the pediatric ESCAPE trial may have allowed more accurate monitoring of the achieved BP than 
achieved in the adult trials, where only casual BP readings were obtained.  
Nevertheless, in all adult studies, patients with proteinuria seemed to benefit from intensified 
BP control, while there was no significant effect in patients without proteinuria. Furthermore, 
a recent meta-analysis including almost 80,000 patients from 21 randomized clinical trials 
demonstrated that the drug-induced reduction of albuminuria is predictive of subsequent 
nephroprotection (178).  
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7. THERAPEUTIC APPROACH  
7.1. When to initiate antihypertensive treatment  
The decision to initiate antihypertensive treatment should not be taken on BP levels alone, but 
should consider the total risk for CV and renal events. The presence or absence of TOD, and 
other risk factors for CV morbidity and mortality such as family history of CV diseases, 
hyperlipidemia, renal diseases or diabetes establish the global CV risk. In children with 
remediable secondary HTN, specific treatment of the underlying disease (renal, endocrine, CV) 
must be initiated immediately after detection. However, in those with primary HTN, 
antihypertensive therapy should first target the risk factors for BP elevation (i.e. 
overweight/obesity, increased salt intake, low physical activity) in the same way as described 
in section 8.1. of “Lifestyle changes”. Lifestyle changes (non-pharmacological therapy) should 
be initiated in youths with high-normal BP also. It should be continued even after starting 
pharmacological therapy, as it can improve the overall CV risk profile in hypertensive children.  
The decision about when to initiate pharmacological therapy cannot be supported by 
mortality/morbidity trial evidence, which is lacking because in children eventual outcomes are 
expected after a long time incompatible with the duration of a controlled trial. Consequently, 
the suggestions indicated in the decision-making tree of Figure 7.1.1 are formulated in analogy 
with what has been demonstrated in adults, and are largely based on wisdom. 
Pharmacological therapy should be started in all children with symptomatic HTN, hypertensive 
TOD, secondary HTN or DM1 or DM2, as well as in those who are unresponsive to non-
pharmacological therapy (179), i.e. those who have persistent HTN despite non-
pharmacological therapy for about 1 year. It  may be considered individually in children with 
high-normal BP if hypertensive TOD is already present (180,181)   
 
7.2. Goal of treatment  
Blood pressure control in hypertensive patients has two major treatment objectives: the 
prevention of CV events and renal damage (or deterioration of renal function in patients with 
already existing CKD). However, the evidence for a specific BP goal in children is scarce and 
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there is uncertainty as to the relative roles of BP targets and drug specific effects on CV and 
renal outcomes. 
 
7.2.1. Blood pressure target in the general hypertensive pediatric population 
In the absence of prospective long-term studies on the impact of different BP levels on 
intermediate or major CV and renal end-points in children, the 95th percentile is considered as 
cut-off for defining HTN in children and adolescents. This provides a rationale for targeting 
children and adolescents with essential HTN to a BP below the 95th percentiles for age, sex 
and height, but it is probably wiser and safer to aim at a BP below the 90th percentile provided 
this goal can be attained by well tolerated treatment (see Table 7.2.1). 
 
7.2.2. Home and 24-hour ambulatory blood pressure target 
Ambulatory BP monitoring is regarded to substantially add to the diagnosis and monitoring of 
HTN, particularly because it can detect both white-coat and masked hypertensives. In children 
with renal HTN a substantially less variable BP response to antihypertensive treatment was 
observed when using ABPM as compared to office BP monitoring only (182), supporting the 
use of ABPM to monitor attainment and maintenance of BP targets. As ABPM cannot be 
performed very frequently, office and home BP monitoring should be utilized routinely. It 
appears appropriate to aim for the same target percentiles for all three modalities of BP 
assessment (7, 56, 64, 183). Blood pressure goal in hypertensive children (for office, home and 
ABPMs) are shown in Table 7.2.1. 
 
7.2.3. Blood pressure target in diabetic and renal disease 
The current European (92) and US guidelines (184) recommend a target BP below 140/90 
mmHg in adults with CKD due to insufficient published evidence for an additional benefit of an 
even lower target concerning mortality or CV or cerebrovascular morbidity. However, the 
National Institute of Health recently carried out the Systolic Blood Pressure Intervention Trial 
(SPRINT), a randomized controlled trial comparing SBP targets of 140 and 120 mm Hg 
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respectively in 9,300 hypertensive adults aged 50 years and older (185). Results of this trial 
would not seem generalizable to children and adolescents because the SPRINT was on older 
adults at high risk for CV events what seems far removed from a pediatric setting (186). 
For children with CKD, the prospective randomized ESCAPE trial has  provided evidence that 
strict BP control aiming for a 24-h BP target below the 50th percentile leads to improved long-
term renal survival (25). On average 1.9 antihypertensive drugs (including the ACE inhibitor 
ramipril provided at a fixed dose) were required to achieve the lower BP target. A post-hoc 
analysis indicates similar renal outcomes occurred with any 24-h BP below the 75th percentile, 
whereas 5-year renal survival increasingly deteriorated when achieved BP  remained above 
this cutoff level (25,187).  
Proteinuria is an important modifier of the renoprotective efficacy of intensified BP control. 
The renal survival benefit of intensified BP control appears limited to children with - even mild 
- proteinuria (188,189). Hence, at the current state of knowledge it appears appropriate to 
target BP to the 75th percentile in children with non-proteinuric CKD and to below the 50th 
percentile in children with proteinuria of any degree with close monitoring of creatinine. 
Although overt diabetic nephropathy is rarely observed in children with diabetes, these 
patients are considered at increased long-term risk for HTN and renal damage (190,191). 
Subtle alterations such as slight increases of SBP and/or a blunted circadian BP variation are 
commonly found by ABPM early in the course of the disease (191,192) when office BP is still 
normal. Impaired nocturnal dipping often precedes microalbuminuria, the earliest marker of 
diabetic nephropathy (191). Although pediatric evidence regarding the efficacy of preventive 
antihypertensive and antiproteinuric treatment strategies in juvenile diabetes is still lacking, 
ample experience with adult diabetes reinforces the recommendation of aiming at a strict BP 
control in children with diabetes. 
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8. TREATMENT STRATEGIES  
8.1. Lifestyle changes  
Considerable advances have been made in recent years in identifying conditions often 
associated with and considered responsible for high BP in children and adolescents. More 
limited evidence has been accumulated on the results of corrective interventions. In 
overweight and obese children it has been demonstrated that lifestyle interventions 
incorporating a dietary component along with exercise or behavioural therapy can lead to 
improvements in both weight and cardiometabolic factors, including BP (193). In overweight 
adolescents weight reduction is associated with a decrease in office BP (194,195) and is the 
primary therapy for obesity-related HTN (1). After one year of lifestyle intervention, changes in 
obesity measures were closely related to changes in 24-h, daytime and night-time BP (196).  
Children with insufficient physical activity are about 3 times more likely to have elevated BP (1) 
and regular physical activity has CV benefits. Meta-analysis concluded that short-term physical 
activity leads to a small but not significant decrease in BP (197). However, regular physical 
activity results in a significant reduction of BP, not only when measured in the office, but also 
when monitored for 24-h BP. After 3 months of exercise training the effects on BP were 7-12 
mmHg for SBP and 2-7 mmHg for DBP (198). Higher levels of physical activity were associated 
with lower BP and results suggested that the volume of activity might be more important than 
the intensity (199). The recommendations for physical activity (200) are included in Box 4. 
Although children less than 5 years old benefit from being active, more research is needed to 
determine what dose of physical activity provides the greatest health benefits.  
Prospective studies have shown the effects of diet on lifetime BP (201). Consumption of >1 
servings of dairy products/day and >2 servings of fruits and vegetables/day throughout 
adolescence has shown to lead to about a 35% lower risk of elevated BP (202). Likewise, 
saturated fat–reduced diet since infancy decreases BP (203). Higher sugar sweetened beverage 
consumption is associated with higher SBP in adolescents (204). High salt intake in children 
and adolescents is positively correlated with high SBP and an elevated risk of HTN (205) and a 
meta-analysis has shown that a 3g/day reduction of salt intake leads to a decrease in SBP and 
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DBP of 1.2/1.3 mmHg (206). Starting in newborns, a 15 year follow-up study has suggested a 
predictive role of the effect of salt intake in early life on BP (207). Excessive salt intake seems 
to be not only linked with BP elevation but also with other CV risk factors since salt produces a 
reduction in vascular nitric oxide bioavailability that limits endothelium-dependent dilation 
(208).  
Environmental exposure to tobacco is an important risk factor contributing to the 
development and severity of CV disease. The heart and vascular system are highly vulnerable 
to tobacco smoking. Discouraging maternal smoking and maintaining a strictly smoke-free 
environment are of great importance due to the accumulating evidence on the importance of 
fetal and early life factors in determining CV risk (209). In adolescents, promotion of smoke-
free rules at home may help prevent the uptake of cigarettes. While in active smokers, 
cessation of smoking is mandatory in order to improve CV risk due to the acute pressor effect 
that may raise daytime ambulatory BP (92). In box 4 the life style recommendations and goals 
are summarized. 
 
8.2. Pharmacological Therapy  
8.2.1. Therapeutic orphans and Regulatory Issues  
There is a general paucity of high quality efficacy and safety data for the large majority of 
drugs used to treat HTN in children. As a consequence of this, dosing and assumptions about 
the therapeutic risk/benefit-ratio of many drugs is based on data derived from studies in 
hypertensive adults. Attempts have been made to improve this inequity through legislation on 
both sides of the Atlantic. The 1997 US Food and Drug Administration Modernization Act 
contained a provision granting a 6 month patent protection to industry if pediatric studies 
were conducted for new drugs. The subsequent Best Pharmaceuticals for Children Act, 
Pediatric Research Equity Act and FDA Amendments Act of 2007 have led to further initiatives, 
including the online public posting of internal FDA pharmacology and efficacy reviews and 
mechanisms to promote studies of drugs with expired patents. In Europe, the Regulation of 
Medicinal Products for Pediatric Use (EU Regulation 1901/2006/EC) similarly provided a six-
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month extension of market exclusivity for new drugs where approved pediatric studies were 
conducted.  For drugs no longer under patent protection, the Paediatric Use Marketing 
Authorisation (PUMA; Art. 40, EU Regulation) provides ten years of market protection as a 
reward for performing appropriate studies as part of an agreed Paediatric Investigation Plan.  
These legislative changes have resulted in a substantial growth in the number of studies of 
antihypertensive (and other) agents being conducted in children and a commensurate increase 
in the number achieving a pediatric licence. However, these studies have principally been 
restricted to newer antihypertensive agents; to date no older drug has received licensing as a 
result of PUMA (EMA). 
 
8.2.2. Choice of antihypertensive drugs  
8.2.2.1. Monotherapy 
When prescribing antihypertensive therapy for adults, decisions regarding the choice of agent 
can be based upon evidence from clinical trials in a large numbers of subjects, many of these 
having compared one class of agent with another (210). While an increased emphasis on 
conducting drug trials in children and adolescents over the past 15 years has yielded important 
advances, there remains a general lack of high quality long-term outcome data to guide choice 
of drug therapy for pediatricians managing HTN. It is important to understand that what works 
for adults does not necessarily work for children and adolescents. 
Those trials that have been conducted have mainly investigated the BP reducing effects of 
single agents in isolation, with very few comparing drugs of the same or different class to 
assess relative efficacy or safety. One exception is a study comparing valsartan with enalapril, 
which showed similar efficacy and adverse event rates for these two agents (211).  Follow-up 
studies are generally limited in duration and little is known about the long term effects of 
antihypertensive agents on many outcomes, including growth and cognitive development. A 
recent Cochrane review identified a total of 21 randomised controlled trials of at least two 
weeks duration comparing antihypertensive agents as either monotherapy or combination 
therapy with either placebo or another medication, or comparing different doses of the same 
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medication in a total of 3454 children with HTN (212). Outcomes were limited to BP with no 
study investigating efficacy of preventing target end organ damage. The most data are 
available for candesartan, which has demonstrated low-quality evidence of a modest lowering 
effect on BP. No evidence could be found of a consistent dose response relationship for 
escalating doses of angiotensin receptor blockers (ARBs), calcium channel blockers and 
angiotensin converting enzyme (ACE) inhibitors. Side effects were generally minor, including 
headaches, dizziness and upper respiratory infections.  
Until such time that high quality clinical trial data are available to compare one class of 
antihypertensive drug with another, several different agents may potentially be first-line 
agents. These include the five classes for which evidence of CV event reduction is available in 
adults (213), ACE-inhibitors, ARBs, beta-blockers, calcium channel blockers and diuretics. 
Clinicians who care for children and young adults with HTN need to be familiar with at least 
one drug from each class of agent. Given the substantial efforts that have been made to 
perform pediatric-specific studies confirming (at least short term) efficacy and safety in 
children, it seems sensible to commence therapy with those agents which have a license for 
use in children. 
It is logical to choose an agent which can be administered once-daily because of the benefits 
that this provides in terms of simplicity of administration, allowing tablet-taking to be 
incorporated into the patient’s daily routine (e.g. bedtime, tooth brushing etc.) and avoiding 
having to take drugs during school hours. Once-daily administration of medicines is also widely 
recognised to improve adherence (214).  
Drug choice should be targeted to the child’s underlying pathophysiology and presence of 
concurrent disorders. For instance, in a child with HTN associated with DM and 
microalbuminuria, or with CKD and proteinuria, an ACE inhibitor or ARB is the most 
appropriate first line agent because of their antiproteinuric effect. Similarly a beta-blocker or 
calcium channel blocker is the most appropriate agent in the child with HTN and migraine or 
where HTN has persisted after coarctation repair; and a diuretic most appropriate in the child 
with corticosteroid-induced HTN. Alternatively, there may be compelling reasons to avoid 
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certain agents, for instance beta-blockers in the hypertensive child with asthma or diabetes, 
and ACE inhibitors or ARBs in female teenagers at high risk of pregnancy. Diuretics and beta-
blockers should generally be avoided in competitive athletes; these may impair performance 
through decreased intravascular volume and decreased cardiac output respectively and are 
also listed among doping substances (215).  
Primary HTN is a growing problem in the pediatric age group, intrinsically linked to the 
increased global incidence of obesity. There is some evidence to suggest the use of ACE 
inhibitors and ARBs as first line agents in the obesity-linked primary HTN population; in adults 
these agents appear to reduce the incidence of new-onset diabetes and may increase insulin 
sensitivity (216). Where these are not tolerated, calcium channel blockers are a reasonable 
alternative. Given their known effects on glucose metabolism and insulin resistance it is 
sensible to avoid the use of beta-blockers without vasodilatory capacity and thiazide diuretics 
(217).  In children with HTN not related to obesity there are no substantial data upon which to 
make a recommendation to support the use of any one agent over another. 
Once the appropriate agent has been selected, the child should commence on the lowest 
recommended dose (see Table 8.2.1 and 8.2.2) (1,218). This dose should be up-titrated until 
the BP falls within the target range or until the maximum recommended dose is reached, at 
the same time carefully monitoring for the development of side-effects. These are drug-
specific and some require routine monitoring, e.g. the assessment of kidney function and 
potassium balance in children receiving ACE inhibitors and ARBs. Drug-related side effects may 
be dose limiting, resulting in the early addition of a second agent or complete replacement of 
the initial agent. 
Monogenic forms of HTN are rare disorders, occurring as a result of single gene mutations and 
characteristically associated with low renin levels with alterations in acid base and potassium 
levels. Their recognition is important because patients are readily treated by a specific 
antihypertensive agent which targets the defective tubular function. Presenting features and 
appropriate therapies are shown in Table 8.2.3 (adapted from 215). 
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8.2.2.2. Combination therapy 
Where the use of the maximum recommended or tolerated dose of any single agent does not 
successfully achieve target BP, then the use of combination therapy is recommended. There is 
no evidence  in the current pediatric literature to support the use of one particular 
combination over another, though some guidance based on adult data is provided in the 
ESH/ESC 2013 Guidelines (92) (Figure 8.2.1). It is logical to combine agents from different drug 
classes and preferably those with complementary modes of action, e.g. an ACE inhibitor with a 
diuretic or a vasodilator with a diuretic or a beta-blocker. Following the review of adult data 
from the ONTARGET (219), ALTITUDE (220) and VA NEPHRON-D (221) studies, the European 
Medicines Agency have formally recommended that no two drugs which act separately on the 
renin-angiotensin system should be used in combination because of risks of hyperkalaemia, 
impaired kidney function and hypotension (www.ema.europa.eu).  Dual therapy with ACE 
inhibitors, ARBs and direct renin inhibitors should therefore be avoided, although it may be 
cautiously used in patients with heavy proteinuria under strict renal function and potassium 
levels monitoring. Few data exist on the use of fixed-dose combination agents in children and 
these are rarely used, though may have a place in the treatment of adolescents with the aim of 
improving medication adherence (222). 
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9. THERAPEUTIC APPROACHES IN SPECIAL CONDITIONS  
9.1. Diabetes mellitus  
Consensus-based guidelines have recommended, mostly on the basis of expert opinion, that 
measures to prevent persistent microalbuminuria, such as optimal blood glucose control, 
participation in physical activity, a low-protein diet, smoking cessation, and BP control, should 
be promoted (152). Blood pressure treatment includes defining the BP goal, how achievement 
of this goal will be checked, and which class of antihypertensive drug will be more appropriate.  
The BP goal for diabetic patients is a relevant and controversial issue in children as well as in 
adults. In the latter no clear evidence is available that the BP should be lower in diabetic than 
in nondiabetic hypertensives (92). In children   longitudinal studies with CV or renal events are 
absent.  Because of some evidence that youths with DM1 or DM2 develop early 
atherosclerotic lesions before the age of 30 (218), the American Heart Association suggests the 
BP goal be lower than the 90th percentile for age, sex and height (152). A post-hoc analysis of 
a trial on DM1 suggests that a lower BP target may be beneficial in reducing urinary albumin 
excretion (UAE) and the risk to develop proteinuria (223). The goals recommended by the 
present panel are indicated in Table 7.2.1: the opinion of the panel is that a goal below the 90th 
percentile (or below 130/80 mmHg at age 16 and above) may be achieved  in both children 
and adolescent, provided treatment is well tolerated.  
At the time to select the antihypertensive drugs two key issues should be considered, the most 
relevant is to achieve the BP goal over the 24 hours and the necessity to reduce salt-intake due 
to the sodium-dependent component of HTN in diabetes (224).   An additional benefit of 
starting with drugs blocking the renin angiotensin system (either ACE inhibitor or ARB),  is 
promised by their ability to reduce urinary albumin excretion and delay the onset of 
nephropathy, although the advantage in long-term protection  has not been established (225). 
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9.2. Heart failure  
Unlike in the adult, HTN is not a common cause of heart failure in children and adolescents. 
However, children and adolescents with end stage renal failure, diabetes, congenital heart 
disease or Kawasaki disease are at increased risk of early CV events and heart failure and the 
management of HTN in these patients needs special attention (226). First-line therapy includes 
salt restriction and agents that target the renin-angiotensin-aldosterone-system combined 
with beta-blockers in low doses if necessary to achieve BP control. Addition of diuretics is 
recommended in patients with volume overload (175,176). Occasionally one may see patients 
with critical CoA presenting with heart failure and upper limb HTN. Surgical or catheter 
intervention to relieve the obstruction is the first treatment of choice. However, HTN may 
persist in some patients despite successful repair (see chapter 11.8) 
Treatment of a hypertensive crisis causing acute heart failure includes the use of intravenous 
vasodilatory agents (nicardipine), with nitroprusside limited to situations where other agents 
fail, or to brief periods of time (227) (see secion 9.6 and Table 9.6.1). 
 
9.3. Non-diabetic renal disease    
In section 7.2 ‘Goal of treatment’, the current evidence is summarized suggesting that HTN in 
children with CKD, especially if accompanied by proteinuria, requires more intense 
management in order to reduce proteinuria and prevent progressive deterioration of renal 
function. Although non-pharmacological options should be considered, drug treatment 
remains the mainstay of antihypertensive management in all stages of CKD. The different 
classes of antihypertensive agents are comparable with respect to their BP-lowering efficacy in 
children with CKD (228,229), but most of the available clinical evidence has been obtained with 
drugs blocking the renin-angiotensin system (RAS) (25,228,230). They have a powerful, dose-
dependent antiproteinuric action in pediatric nephropathies (231). RAS inhibitors in general 
have a favourable side effect profile; however, a few fatalities have been documented in 
infants with acute intravascular volume depletion while receiving angiotensin receptor 
blockers (231,232). It is recommended to use RAS blocking agents as first choice with 
40 
 
appropriate risk counselling in all proteinuric patients with CKD. In hypertensive infants with 
non-proteinuric CKD, calcium channel blockers may be considered as first-line therapy for 
safety considerations.     
In three-quarters of hypertensive children with CKD stage 2-4, BP control can be achieved by 
antihypertensive monotherapy, but at least 50% of children require more than one drug to 
achieve a sufficiently low BP target. If multiple drug therapy is required, diuretics and calcium 
channel blockers are the most suitable addition to a RAS blocker . Whereas the combined 
administration of ACE inhibitors, ARBs and the renin inhibitor aliskiren exert additional 
antiproteinuric effects in adults and children (233,234), it is recommended not to use such 
combination therapies because of increased rates of serious adverse events such as acute 
kidney injury and hyperkalemia observed in large randomized trials of high-risk adult patients 
(219-221).  
 
9.4. Metabolic syndrome  
Despite the difficulties in defining metabolic syndrome in children and adolescents (see section 
5.2.), the construct of clustering of cardiometabolic risk factors are useful in the clinical setting. 
The key issue is to reduce the highly prevalent overweight and obesity, a complex task to 
maintain overtime. All effort should be done to educate young people as early as possible to a 
healthy lifestyle. A combination of physical exercise plus dietary intervention is commonly 
required. Several complementary actions, such as family- and school-based interventions and 
benefiting from internet-delivered intervention, are crucial to achieve success (235). 
Information about the use of drugs to reduce obesity and/or increase insulin sensitivity is 
scarce, but the CV serious side effects of sibutramine (236) and the gastrointestinal side effect 
of orlistat do not recommend their use. The use of metformin for abdominal obesity seems to 
be effective in the short-term but information about the efficacy overtime is lacking (237). 
Besides intervention for obesity, the rest of the cardiometabolic risk factors should be treated, 
aiming not to increase weight or insulin resistance. For HTN, thiazide diuretics and classic beta-
blockers are not recommended, while drugs that block the renin-angiotensin system are 
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preferable (92,238). If beta-blockers are a compelling indication, those with vasodilating 
capacity should be used. A controversial issue is the role of hyperuricemia in the risk of 
developing HTN and CV risk, but today not significant evidence exists to give grounded 
recommendations. 
 
9.5. Resistant hypertension  
Hypertension may be termed resistant to treatment, or refractory, when a therapeutic plan 
that has included attention to lifestyle measures and the prescription of at least three drugs in 
adequate doses (one diuretic) has failed to lower systolic and DBP sufficiently (92). This 
condition implies very high CV and renal risk and requires prompt intervention. In children and 
adolescents, once white coat and adherence to treatment has been checked, there is always a 
secondary cause of HTN. Even though there are no systematic studies reporting secondary 
causes of resistant HTN, primary glomerulopathies, renal insufficiency, vascular diseases and 
neurological tumours are the most frequent diseases. In these cases it is not difficult to 
diagnose with simple analytical or image technique procedures. If this is not the case, genetic 
causes of HTN should be ruled out. 
Among the genetic causes the most common are the sodium-dependent ones, although some 
others should be taken into account such as autosomal dominant brachydactyly with HTN 
associated with increased activation of pressure centres in brain stem and increased peripheral 
vascular resistance.  
 
9.6. Hypertensive emergencies  
A hypertensive emergency is a life-threatening condition associated with severe HTN. Although 
there is no absolute level of BP to define severe HTN some authors suggest to use a cut-off of 
20% above the stage 2 HTN limit, which corresponds with an SBP of 178 mmHg in a 17 year old 
boy (239). This should be differentiated from a hypertensive urgency that is defined as severe 
HTN without acute target organ dysfunction.  
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Life-threatening conditions include organ dysfunction, mainly neurological, renal or cardiac. 
The most common symptoms of a hypertensive crisis are headache, dizziness, 
nausea/vomiting, seizures, confusions, visual symptoms and facial nerve palsy (240). Acute 
encephalopathy syndromes can also be produced with no extreme BP elevations when the 
HTN appears as a sudden onset, since the autoregulation of cerebral flow is not able to control 
the rapid BP increment. 
The etiology of HTN causing a hypertensive crisis is mostly secondary (renal, endocrine, or 
cardiac). The evaluation of a child with a hypertensive emergency should include fundoscopic 
exam (hemorrhages, exudates, papilledema) and neurologic clinical evaluation and CT (to 
exclude hemorrhage) or MRI (for edema of white matter in the parieto-occipital regions, 
named PRES) in case of symptoms of hypertensive encephalopathy.   
Children with hypertensive emergencies should be treated in an intensive care unit to ensure 
monitoring and support of the vital organs including neurologic status. The treatment strategy 
must be directed towards the immediate reduction of BP to reduce the hypertensive damage 
to the target organs, but not at a rate that would be likely to cause hypoperfusion of vital 
organs by an excessively rapid reduction of BP (mainly cerebral hypoperfusion with 
neurological sequelae or renal hypoperfusion with acute kidney injury).  
There is no experimental evidence upon which recommendations on the optimal rate of BP 
reduction in hypertensive emergencies could be based. From clinical experience, BP should be 
lowered by no more than 25% of the planned BP reduction over the first 6-8 hours, followed 
by a further gradual reduction over the next 24-48 hours (227,241-244). Faster normalisation 
of severe HTN must be strictly avoided as it can cause more harm than severe HTN itself. Then, 
careful neurological and CV assessment should be undertaken throughout the initial 
treatment. 
Children with a hypertensive emergency should always be treated with intravenous drugs. 
Continuous infusion is safer than bolus in regard to complication (unexpected hypotension 
with vital organ hypoperfusion and irreversible neurological damage such as visual loss). 
Sodium nitroprusside and labetalol are the most commonly used drugs for hypertensive 
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emergencies in children. However, some drugs are no longer available in some countries. 
Hypertensive urgencies can be treated by oral drugs. Table 9.6.1 indicates drugs and doses 
used for pediatric hypertensive crises. 
 
9.7. Malignant hypertension 
Malignant HTN was classically defined by the presence of an acute increase of BP values, with 
or without previous HTN, and a funduscopy stage III or IV. Today it is considered an acute 
elevation of BP associated with impairment of at least three different target organs or even 
the presence of microangiopathic haemolytic anaemia. The prevalence of malignant HTN has 
clearly fallen with the advent of anti-hypertensive medication. Early recognition and 
management of malignant HTN are fundamental to any improvement in prognosis, although 
parenteral drug administration is not necessary (245). 
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10. TREATMENT OF ASSOCIATED RISK FACTORS  
10.1. Lipid lowering agents 
The 2011 National Heart, Lung, and Blood Institute Integrated Guidelines for Cardiovascular 
Health and Risk Reduction in Children and Adolescents (218) recommend to consider statin 
therapy for children >10 years with LDL-C levels of ≥190 mg/dL (< 4.9 mmol/L) without other 
risk factors, or ≥160 mg/dL (<4.1 mmol/L) if additional risk factors are present and in those 
with LDL-C levels >130 mg/dL (>3.4 mmol/L) after 6 months of lifestyle changes. In contrast, 
the 2013 American College of Cardiology and American Heart Association Guideline on the 
Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults  
recommends medication for individuals younger than 40 years only if their LDL-C level is at 
least 190 mg/dL (4.9 mmol/L) (246). Children <10 years should not be treated with a lipid 
lowering medication unless they have a severe primary familial hyperlipidemia or high-risk 
conditions. Given the conflicting lipid treatment guidelines for youth and current uncertain 
state of knowledge on long-term safety of statin therapy (247,248), the panel recommend to 
initially address modifiable risk factors such as diet, exercise, weight and abstinence from 
tobacco, and institute a lipid-lowering therapy only after careful evaluation of  potential 
benefits, harms, and patient preferences. In children on statins, monitoring of hepatic enzymes 
and clinical assessment for muscle toxicity are strongly recommended.  Fish oil should be used 
to reduce triglyceride levels. 
 
10.2. Glycaemic control 
Lifestyle changes should be initiated at the time of diagnosis of DM2 as well as in children with 
hyperglycaemia and elevated risk of DM2. Nutritional advice must focus on eliminating sugar-
containing soft drinks, increasing fruit and vegetable intake, reducing processed, pre-packaged 
food and controlling portions. Youths should be encouraged to engage in moderate-to-
vigorous exercise for at least 60 min daily. Initial pharmacologic treatment for children with 
DM2 should include metformin and insulin, alone or in combination, depending on symptoms, 
severity of hyperglycemia, and presence or absence of ketosis/ketoacidosis (225).  The TODAY 
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Study compared the efficacy of three treatment regimens to achieve durable glycemic control 
in 699 children and adolescents with recent-onset DM2 (249). Results showed that metformin 
alone is effective in maintaining durable glycemic control in only half of children, and the 
addition of rosiglitazone, but not intensive lifestyle intervention, is superior to metformin 
alone. These findings suggest that most children require a combination treatment or insulin 
therapy within a few years after diagnosis and that more effective lifestyle regimens for 
children must be identified. Several clinical trials of newer oral hypoglycemic agents are 
underway in DM2 youth, but recruitment is slow and results are not expected for many years. 
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11. SCREENING AND TREATMENT OF SECONDARY FORMS OF HYPERTENSION  
11.1. General strategy to when and how to look for secondary hypertension in children and 
adolescents  
Secondary HTN is generally accepted to be much more common in children and adolescents 
than in the adult population, with some studies reporting prevalence as high as 75-85% in 
younger children (250-252).  More recent reports, however, have highlighted the increasing 
prevalence of primary HTN, which is strongly linked to childhood obesity, particularly in the 
adolescent population. 
Secondary HTN should be suspected in the younger patient in whom there is a very high BP or 
secondary complications (hypertensive encephalopathy, cranial nerve palsy, heart failure etc.) 
or HTN is difficult to treat. A good general rule to follow is that the likelihood of identifying a 
secondary cause of HTN is inversely related to the age of the child and directly related to the 
degree of BP elevation (253).  
The clinical history should identify potential indicators to a secondary cause for HTN, including 
previous urine infection, gross haematuria or oedema, episodes of acute kidney injury, 
umbilical artery catheterisation, vascular events, snoring and sleep problems suggestive of 
obstructive sleep apnoea and any strong family history of HTN at a young age. Examination 
should seek to identify clinical signs suggestive of systemic disorders associated with HTN 
(refer to Table 4.4.1). In general, young children, children with very high or complicated HTN, 
and those with the aforementioned clinical symptoms and signs should be investigated more 
extensively than the older child with seemingly mild HTN. 
 
11.2. Renal parenchymal disease  
Since the most common form of secondary HTN in children and adolescents are diseases of the 
renal parenchyma, screening to detect an underlying cause of HTN should start with specific 
tests to detect renal abnormalities. This includes urine analysis (hematuria, proteinuria) and 
blood tests (creatinine, urea, uric acid, electrolytes) as well as renal function tests (1). For the 
diagnosis of chronic glomerular diseases renal biopsy is often necessary to clarify the form of 
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glomerulonephritis and the degree of glomerular damage, and a special kind of involvement, 
e.g. focal segmental glomerulosclerosis. Ultrasonography is able to detect autosomal-
dominant and autosomal-recessive forms of polycystic kidney diseases, renal dysplasia or 
reflux nephropathy. Reflux nephropathy (pyelonephritic scarring) results from vesicoureteric 
reflux combined with urinary-tract infection in early life, and requires a micturition 
cystourethrography. Additional techniques of renal imaging (e.g. scintigraphy CT, MRI) are 
seldom needed. In cases of suspected genetic disease (e.g. Alport syndrome, congenital 
nephrotic syndrome) genetic testing is required. For treatment approach see section 9.3. 
 
11.3. Renovascular hypertension 
Diseases of the renal vessels resulting from lesions that cause significant impairment of blood 
flow to kidneys are far rarer than diseases of the renal parenchyma. The most single cause of 
renovascular HTN in children is fibromuscular dysplasia (254). Stenosis of the renal artery is 
not often associated with neurofibromatosis, but it should be excluded. Also other syndromes, 
e.g.   Klippel–Trenaunay, Turner and Alagille syndrome have to be considered (255).  
Plasma renin activity is often recommended to detect renovascular HTN, but it is not sensitive 
or specific and has a role to detect low renin HTN, mainly monogenic forms of HTN. Imaging 
procedures by abdominal ultrasound including colour-aided and Doppler sonography of the 
renal artery shows increased systolic and particularly diastolic flow velocity in the renal 
arteries. MRI angiography is more sensitive and specific to demonstrate abdominal or renal 
artery stenosis; this is the diagnostic procedure of choice. However, its sensitivity and 
specificity is lower than the gold standard procedure, i.e. renal angiography.   
Renal artery revascularization is often able to control HTN in fibromuscular dysplasia (256). 
When angioplasty is not effective, surgical procedures should be chosen as the next 
therapeutic approach (257). 
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11.4. Phaeochromocytoma  
Pediatric pheochromocytomas and extra-adrenal catecholamine-producing tumours are more 
frequently familial, bilateral, multifocal and malignant. Half of these tumours are associated 
with a mutation of one of the 12 known susceptibility genes. These tumours are often 
identified during presymptomatic screening in children with genetic syndromes such as 
multiple endocrine neoplasia type 2, von Hippel-Lindau disease, type 1 neurofibromatosis and 
the paraganglioma syndromes (258,259). Plasma and/or urine metanephrine measurement 
and MR imaging are recommended as first-line diagnostic approach. Surgical resection, with 
appropriate perioperative management of catecholamine-related symptoms, is the treatment 
of choice. In the case of metastatic disease, surgical removal of metastases and I-131-MIBG 
radiotherapy can be performed (258,259). 
 
11.5. Primary aldosteronism  
Primary aldosteronism is characterized by HTN with low plasma renin and elevated 
aldosterone and often associated with hypokalemia. An early-onset primary aldosteronism 
suggests inherited causes. Three familial aldosteronisms have been described: FH-1 
(glucocorticoid-remediable aldosteronism caused by mutations affecting aldosterone 
synthase), FH-2 (with unknown molecular basis), and FH-3 (two distinct syndromes with or 
without adrenal hyperplasia resulting from different mutations in genes coding for ion 
channels) (260). FH-1 is associated with high morbidity and mortality at an early age and 
should be treated in children with eplerenone to avoid glucocorticoid effects on growth or 
antiandrogenic effects of spironolactone. Children with FH-3 and bilateral adrenal hyperplasia 
present with severe HTN refractory to treatment and need bilateral adrenalectomy. FH-2 is 
clinically and biochemically indistinguishable from sporadic forms (260).  
 
11.6. Cushing’s syndrome  
In children  >7 years of age the most frequent cause of endogenous Cushing syndrome (CS) is 
an ACTH-secreting pituitary microadenoma (75%), whereas adrenocortical tumours (70% 
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malignant) are more common in younger children. Micronodular adrenal hyperplasia can also 
occur as part of genetic disorders such as the McCune–Albright syndrome and the primary 
pigmented bilateral adrenocortical nodular disease (261). This latter may be associated with 
Carney complex (multiple endocrine tumors, lentigines and myxomas). The most common 
presenting features are weight gain and growth retardation. Hypertension is present in about 
half of children with CS. High SBP levels persist one year after surgery in 5.5-21% of children 
(262,263). 
 
11.7. Obstructive sleep apnea  
Prevalence of sleep-apnea syndrome in children is around 2-3% in the general population 
(264), although among obese adolescents the prevalence varies between 13% and 66% (265- 
268). Dayyat et al. (269) described two types of obstructive sleep apnea (OSA) in children. 
While Type I is characterized by amigdalar hypertrophy, mild overweight, hyperactivity, and 
with recurrent infections, Type II is present in obese subjects with diurnal hypersomnia, HTN 
and metabolic disturbances. Nocturnal pulsioxymetry can identify children and adolescents at 
high risk of OSA. During monitoring, three or more desaturations per hour have up to 97% 
predictive value in children without any other health problem. However, if the test is normal, 
this does not exclude the presence of OSA, as the test has a 47% negative predictive value. 
Several studies have linked OSA and the alterations in the glucose metabolism with insulin 
resistance, besides the BP elevation. The mechanisms that link obesity, OSA and insulin 
resistance are controversial. Some authors defend the hypothesis that the sleep fragmentation 
and the nocturnal hypoxia are responsible for insulin resistance (270), increment of cortisol, 
overdrive of the sympathetic nervous system (271) and the increment in insulin (272). Others 
consider that the primary alteration is obesity and insulin resistance, resulting in a respiratory 
disorder during sleep, facilitating the collapse of the upper airway through inflammatory 
mediators and a reduction in the neural drive of the dilatory muscle of the airway (273).  
Hypertension treatment in these adolescents should be based on treating obesity. In the most 
severe forms resistant to losing weight, continuous positive airway pressure (CPAP) should be 
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used.  
 
11.8. Coarctation of aorta  
Coarctation of the aorta (CoA) accounts for 5%-7% of all congenital heart disease with an 
incidence of approximately 3 cases per 10000 births (274). Patients with less severe CoA may 
not be diagnosed until later in childhood when a murmur is heard or HTN noted. In addition, 
residual or late-onset HTN is a well-known complication in successfully repaired CoA. The 
chronic burden of HTN in CoA patients is likely significantly higher than in other at-risk 
populations due to the early onset of the illness (275). This population needs to be treated as 
at particularly high risk, and HTN should be aggressively sought and treated. Before 
considering antihypertensive agents a re-coarctation must be ruled out. In children aged 7-16 
years the prevalence of restenosis is suggested to be as high as 21% (276) and masked HTN is 
common, then ABPM should be performed regularly from the age of seven (80). Exercise HTN 
may also be present despite the lack of early or long-term residual or recurrent obstruction. 
The clinical significance of abnormal BP response to exercise is somewhat controversial (277). 
It has been suggested that it is a predictor of chronic HTN (278,279).  
Before considering antihypertensive agents a re-coarctation must be ruled out. Beta-blockers, 
calcium channel blockers and drugs affecting the renin-angiotensin-aldosterone system 
efficiently lower BP (280,281). 
 
11.9. Drug-induced hypertension  
Drug-induced hypertension (DIH) is defined as HTN caused by the unintended effect of a drug, 
or from a drug’s antagonizing effects on antihypertensive treatment (282). The two major 
mechanisms of DIH are sodium retention and sympathomimetic effect (Table 11.9.1). 
Treatment of DIH is by withdrawal of the drug causing DIH and sometimes short term 
antihypertensive treatment may be needed. When therapy with a therapeutic agent causing 
DIH cannot be stopped, chronic antihypertensive treatment should be started. DIH may 
present as resistant HTN or exacerbation of HTN in a child already treated with 
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antihypertensive drugs, or de novo in a previously normotensive child (282,283). The distinct 
cause of DIH is the use of illicit pyschostimulants which exert sympathoexcitatory effect. Oral-
contraceptive drugs should be considered in adolescent girls and should be removed when 
HTN is detected; BP can be increased even after two months of withdrawal. The recent 
introduction in cancer treatment of anti-angiogenic drugs has become a relevant cause of DIH. 
Inhibitors of angiogenesis produce reduced activity of vascular endothelial growth factor 
(VEGF) pathway via tyrosin kinase.  
Treatment of DIH is based on expert opinions and case series. The most frequent DIH, 
mechanism and recommended treatment are in Table 11.9.1. 
 
11.10. Monogenic causes of hypertension  
Monogenic diseases should be suspected in children with low renin HTN and a family history of 
early-onset severe HTN, death from cerebral vascular accidents and heart failure or refractory 
HTN. A trend to hypokaliemia is a common feature of the majority of the low renin 
hypertensive states, with the exception of Gordon’s syndrome.  
Most forms of monogenic HTN are sodium-dependent secondary to mineralocorticoid effect 
caused by mineralocorticoids, cortisol, mineralocorticoid-independent sodium reabsorption by 
epithelial sodium channel (ENaC), activated mineralocorticoid receptor or deoxycorticosterone 
(282,283). Figure 11.10.1 outlines a rational approach to each of the most frequent monogenic 
causes.  Following the clinical suspicion, a specific test should be performed. 
Treatment of monogenic HTN is directed against main pathophysiological disturbances and 
confirmed by results of case series. Treatment of sodium-dependent, low-renin monogenic 
HTN is based on low-sodium diet and blockade of pathological mechanisms of sodium 
reabsorption. Treatment of pseudohypoaldosteronism type II is based on thiazides. Treatment 
of Liddle syndrome and of activating mutation of MR treatment is directed against ENaC and 
based on amiloride or triamterene. In apparent mineralocorticoid excess (defective 
metabolism of cortisol to cortison) treatment is based on dexamethasone, blockers of ENaC 
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and MR. Congenital adrenal hyperplasia associated with HTN, i.e. deficiency of 11β or of 17α 
hydroxylase, is treated with dexamethasone and blockers of MR. Treatment of choice in 
familial hyperaldosteronism type I is dexamethasone and in familial hyperaldosteronism type II 
are blockers of MR. In autosomal dominant brachydactyly with HTN multidrug regimen based 
on beta-blockers  devoided of sympathomimetic action, alpha-blockers  and calcium channel 
blockers are suggested (284). (Figure 11.10.1). 
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12. FOLLOW-UP  
Depending on the underlying cause of HTN, periodic, probably life-long follow-up is advisable 
in the majority of children. Regular home BP monitoring can greatly facilitate the management 
of HTN for better assessing of BP control. In children with CKD or diabetes, regular ABPM 
measurements at 6-12-month intervals are recommended to rule out selective nocturnal HTN. 
In patients with LVH or inadequately controlled BP, cardiac assessment should be repeated at 
least every six months. Fundoscopy should be performed at least annually in patients with 
hypertensive HTNR. Patients with well-controlled HTN and no target organ pathology should 
be monitored at larger intervals, e.g. every 12 to 24 months, to rule out de novo TOD. 
In some patients, in whom treatment is accompanied by an effective BP control for an 
extended period, it may be possible to reduce the number and dose of drugs. This may be 
particularly the case if BP control is accompanied by healthy lifestyle changes, such as weight 
loss, exercise habits and a low-fat and low-salt diet, which remove environmental pressor 
influences. Reduction of medications should be made gradually and the patient should 
frequently be checked because of the risk of reappearance of HTN. 
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13. IMPLEMENTATION OF GUIDELINES AND WHERE TO INTERVENE – Community settings and 
stakeholders 
Synergistic actions at various levels (learned societies and international expert committees, 
general practitioners, pediatricians, nurses and other healthcare providers, schools, parents, 
and policy makers) should be successfully implemented In order to limit, and even reduce, the 
burden of HTN in children and adolescents. The role of learned societies, particularly the ESH, 
is crucial not only for spreading the guidelines all over European Countries, but also for 
obtaining the acceptance by national hypertension societies and leagues. 
In parallel, a concerted public action is needed to both improve identification and treatment of 
high BP among children and adolescents, and to encourage lifestyle factors, namely healthy 
nutrition, low salt intake, non smoking, alcohol avoidance, and exercise activity, as preventive 
and curative measures. Only an aggressive public policy initiative will lead healthcare 
providers, insurers and other payers, to increase the reimbursement of costs associated with 
the investigation and long-term treatment of high BP in children and adolescents. Indeed, a 
comprehensive preventive program in each European country involving all the above actors, as 
well as families and school teachers, is a prerequisite to promoting management 
implementation in practice and improving child and adolescent health. 
A converging action is the only means to closing the gap between experts’ recommendations 
and undiagnosed HTN in children and adolescents, undetected TOD, and poor BP control.  
The writing committee is well aware of the fact that issuing these guidelines does not imply 
implementation.  These guidelines represent a consensus among  specialists involved in the 
detection and control of high BP in children and adolescents.  Scientific evidence derived from 
trials is not available in children, and therefore these guidelines are likely to be modified in 
forthcoming years depending on new evidence to be acquired. The recommendations of the 
present document synthesize a considerable amount of scientific data and clinical experience, 
and represent the best clinical wisdom upon which physicians, nurses and families should base 
their decisions. In addition, because they call attention to the burden of HTN in children and 
adolescents, and its contribution to the current epidemic of CV disease, these guidelines 
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should encourage public policy makers to develop a global effort to improve identification and 
treatment of high BP among children and adolescents. 
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14. FUTURE RESEARCH 
Several times, these guidelines have acknowledged and lamented the lack of solid, trial based 
evidence for recommendations on diagnosis and management of pediatric HTN. Areas 
requiring urgent increase in knowledge have been listed in Box 6.  A commitment to finding 
answers to the outlined issues should guide concerted actions over the next several years in 
Europe.   
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LEGEND OF FIGURES 
 
 
FIGURE 2.1.1. Flow-chart for the diagnosis of hypertension based on Percentile distribution of 
age, sex and height. (< 16 y) and on defined threshold (≥16y) 
P, percentile. 
 
Figure 7.1.1. When to initiate antihypertensive treatment.  
One or more of the conditions listed in the box  are required for the start of antihypertensive 
drugs. Persistent hypertension, despite nonpharmacological measures,  requires initiation of 
antihypertensive drug treatment.  
 
Figure 8.2.1. Recommendation for combination of antihypertensive drugs (From ref 92). 
Green/continuous: preferred. Green/dashed: useful (with some limitations). Black/dashed: 
possible but less well tested. Red/continuous: not recommended 
Only dihydropyridines to be combined with -blockers. Thiazides + -blockers increase risk of 
new onset Diabetes Mellitus. (ACE) Angiotensine converting enzyme + Angiotensine-receptor 
blockers combination discouraged  
 
Figure 11.10.1. Mendelian causes of hypertension. Metabolite profile and recommended 
treatment. 
Diagnostic algorithm in low plasma renin activity hypertension and genetic testing. Ratio of 
urinary THF+alloTHF/THE, normal less than 1.3, apparent mineralcorticoid excess 5-10 fold 
higher. (THE) tetrahydrocortisone; (THF) tetrahydrocortisonl (alloTHF) allotetrahydrocortisol;  
(R) renin; (PRA) Plasma renin activity. (Aldo) aldosterone. (GFR) Glomerular filtration rate.  
(ACTH) Adrenocorticotropic hormone; (AD) Autosomal dominant)  (AR) Autosomal recesive. 
(GRA) Glucocorticoide remediable aldosteronism. Shaded área corresponds to the 
recommended treatment. 
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Table 2.1.1. Classification of hypertension in children and adolescents 
 
 0-15 year 16 year and older 
Category SBP and/or DBP Percentile      SBP and/or DBP values  
Normal 
 
<90th 
 
 
<130/85 mmHg 
 
High-Normal ≥90th to <95th percentile 130-139/85-89 mmHg 
   
Hypertension 
 
Stage 1 Hypertension 
≥95th percentile 
 
95th percentile to the 99th percentile plus 5 mmHg 
 
≥140/90 mmHg 
 
140-159/90-99 mmHg 
 
Stage 2 Hypertension >99th percentile plus 5 mmHg 
 
160-179/100-109 mmHg  
 
Isolated Systolic Hypertension SBP ≥95th percentile and DBP<90th percentile ≥140/<90 mmHg 
Table
Table 2.1.2  Blood pressure for boys by age and height percentiles 
                                                                                                                                                    Systolic (mmHg) percentile of height                                                         Diastolic (mmHg) percentile of height 
Age (years) BP percentile 
5th 10th 25th 50th 75th 90th 95th 
 
5th 10th 25th 50th 75th 90th 95th 
1 90th 94 95 97 99 100 102 103 
 
49 50 51 52 53 53 54 
 95th 98 99 101 103 104 106 106  54 54 55 56 57 58 58 
 99th 105 106 108 110 112 113 114  61 62 63 64 65 66 66 
2 90th 97 99 100 102 104 105 106  54 55 56 57 58 58 59 
 95th 101 102 104 106 108 109 110  59 59 60 61 62 63 63 
 99th 109 110 111 113 115 117 117  66 67 68 69 70 71 71 
3 90th 100 101 103 105 107 108 109  59 59 60 61 62 63 63 
 95th 104 105 107 109 110 112 113  63 63 64 65 66 67 67 
 99th 111 112 114 116 118 119 120  71 71 72 73 74 75 75 
4 90th 102 103 105 107 109 110 111  62 63 64 65 66 66 67 
 95th 106 107 109 111 112 114 115  66 67 68 69 70 71 71 
 99th 113 114 116 118 120 121 122  74 75 76 77 78 78 79 
5 90th 104 105 106 108 110 111 112  65 66 67 68 69 69 70 
 95th 108 109 110 112 114 115 116  69 70 71 72 73 74 74 
 99th 115 116 118 120 121 123 123  77 78 79 80 81 81 82 
6 90th 105 106 108 110 111 113 113  68 68 69 70 71 72 72 
 95th 109 110 112 114 115 117 117  72 72 73 74 75 76 76 
 99th 116 117 119 121 123 124 125  80 80 81 82 83 84 84 
7 90th 106 107 109 111 113 114 115  70 70 71 72 73 74 74 
 95th 110 111 113 115 117 118 119  74 74 75 76 77 78 78 
 99th 117 118 120 122 124 125 126  82 82 83 84 85 86 86 
8 90th 107 109 110 112 114 115 116  71 72 72 73 74 75 76 
 95th 111 112 114 116 118 119 120  75 76 77 78 79 79 80 
 99th 119 120 122 123 125 127 127  83 84 85 86 87 87 88 
9 90th 109 110 112 114 115 117 118  72 73 74 75 76 76 77 
 95th 113 114 116 118 119 121 121  76 77 78 79 80 81 81 
 99th 120 121 123 125 127 128 129  84 85 86 87 88 88 89 
10 90th 111 112 114 115 117 119 119  73 73 74 75 76 77 78 
 95th 115 116 117 119 121 122 123  77 78 79 80 81 81 82 
 99th 122 123 125 127 128 130 130  85 86 86 88 88 89 90 
11 90th 113 114 115 117 119 120 121  74 74 75 76 77 78 78 
 95th 117 118 119 121 123 124 125  78 78 79 80 81 82 82 
 99th 124 125 127 129 130 132 132  86 86 87 88 89 90 90 
12 90th 115 116 118 120 121 123 123  74 75 75 76 77 78 79 
 95th 119 120 122 123 125 127 127  78 79 80 81 82 82 83 
 99th 126 127 129 131 133 134 135  86 87 88 89 90 90 91 
13 90th 117 118 120 122 124 125 126  75 75 76 77 78 79 79 
 95th 121 122 124 126 128 129 130  79 79 80 81 82 83 83 
 99th 128 130 131 133 135 136 137  87 87 88 89 90 91 91 
14 90th 120 121 123 125 126 128 128  75 76 77 78 79 79 80 
  
 
 
 
 
BP, blood pressure. Modified from Task Force on High Blood Pressure in Children and Adolescents (7) 
Shaded area corresponds to reference values of boys 16 years or older in which the reference values for adults are recommended.  
 
 
 
 
 
 
 
 
 
 
 
 95th 124 125 127 128 130 132 132  80 80 81 82 83 84 84 
 99th 131 132 134 136 138 139 140  87 88 89 90 91 92 92 
15 90th 122 124 125 127 129 130 131  76 77 78 79 80 80 81 
 95th 126 127 129 131 133 134 135  81 81 82 83 84 85 85 
 99th 134 135 136 138 140 142 142  88 89 90 91 92 93 93 
16 90th 125 126 128 130 131 133 134  78 78 79 80 81 82 82 
 95th 129 130 132 134 135 137 137  82 83 83 84 85 86 87 
 99th 136 137 139 141 143 144 145  90 90 91 92 93 94 94 
17 90th 127 128 130 132 134 135 136  80 80 81 82 83 84 84 
 95th 131 132 134 136 138 139 140  84 85 86 87 87 88 89 
 99th 139 140 141 143 145 146 147  92 93 93 94 95 96 97 
Table 2.1.3. Blood pressure for girls by age and height percentiles 
 
                                                                    Systolic (mmHg) percentile of height                                                        Diastolic (mmHg) percentile of height 
Age (years) BP percentile 
5th 10th 25th 50th 75th 90th 95th 
 
5th 10th 25th 50th 75th 90th 95th 
1 90th 97 97 98 100 101 102 103 
 
52 53 53 54 55 55 56 
 95th 100 101 102 104 105 106 107  56 57 57 58 59 59 60 
 99th 108 108 109 111 112 113 114  64 64 65 65 66 67 67 
2 90th 98 99 100 101 103 104 105  57 58 58 59 60 61 61 
 95th 102 103 104 105 107 108 109  61 62 62 63 64 65 65 
 99th 109 110 111 112 114 115 116  69 69 70 70 71 72 72 
3 90th 100 100 102 103 104 106 106  61 62 62 63 64 64 65 
 95th 104 104 105 107 108 109 110  65 66 66 67 68 68 69 
 99th 111 111 113 114 115 116 117  73 73 74 74 75 76 76 
4 90th 101 102 103 104 106 107 108  64 64 65 66 67 67 68 
 95th 105 106 107 108 110 111 112  68 68 69 70 71 71 72 
 99th 112 113 114 115 117 118 119  76 76 76 77 78 79 79 
5 90th 103 103 105 106 107 109 109  66 67 67 68 69 69 70 
 95th 107 107 108 110 111 112 113  70 71 71 72 73 73 74 
 99th 114 114 116 117 118 120 120  78 78 79 79 80 81 81 
6 90th 104 105 106 108 109 110 111  68 68 69 70 70 71 72 
 95th 108 109 110 111 113 114 115  72 72 73 74 74 75 76 
 99th 115 116 117 119 120 121 122  80 80 80 81 82 83 83 
7 90th 106 107 108 109 111 112 113  69 70 70 71 72 72 73 
 95th 110 111 112 113 115 116 116  73 74 74 75 76 76 77 
 99th 117 118 119 120 122 123 124  81 81 82 82 83 84 84 
8 90th 108 109 110 111 113 114 114  71 71 71 72 73 74 74 
 95th 112 112 114 115 116 118 118  75 75 75 76 77 78 78 
 99th 119 120 121 122 123 125 125  82 82 83 83 84 85 86 
9 90th 110 110 112 113 114 116 116  72 72 72 73 74 75 75 
 95th 114 114 115 117 118 119 120  76 76 76 77 78 79 79 
 99th 121 121 123 124 125 127 127  83 83 84 84 85 86 87 
10 90th 112 112 114 115 116 118 118  73 73 73 74 75 76 76 
 95th 116 116 117 119 120 121 122  77 77 77 78 79 80 80 
 99th 123 123 125 126 127 129 129  84 84 85 86 86 87 88 
11 90th 114 114 116 117 118 119 120  74 74 74 75 76 77 77 
 95th 118 118 119 121 122 123 124  78 78 78 79 80 81 81 
 99th 125 125 126 128 129 130 131  85 85 86 87 87 88 89 
12 90th 116 116 117 119 120 121 122  75 75 75 76 77 78 78 
 95th 119 120 121 123 124 125 126  79 79 79 80 81 82 82 
 99th 127 127 128 130 131 132 133  86 86 87 88 88 89 90 
13 90th 117 118 119 121 122 123 124  76 76 76 77 78 79 79 
 95th 121 122 123 124 126 127 128  80 80 80 81 82 83 83 
 99th 128 129 130 132 133 134 135  87 87 88 89 89 90 91 
14 90th 119 120 121 122 124 125 125  77 77 77 78 79 80 80 
 95th 123 123 125 126 127 129 129  81 81 81 82 83 84 84 
 99th 130 131 132 133 135 136 136  88 88 89 90 90 91 92 
15 90th 120 121 122 123 125 126 127  78 78 78 79 80 81 81 
 95th 124 125 126 127 129 130 131  82 82 82 83 84 85 85 
 99th 131 132 133 134 136 137 138  89 89 90 91 91 92 93 
16 90th 121 122 123 124 126 127 128  78 78 79 80 81 81 82 
 95th 125 126 127 128 130 131 132  82 82 83 84 85 85 86 
 99th 132 133 134 135 137 138 139  90 90 90 91 92 93 93 
17 90th 122 122 123 125 126 127 128  78 79 79 80 81 81 82 
 95th 125 126 127 129 130 131 132  82 83 83 84 85 85 86 
 99th 133 133 134 136 137 138 139  90 90 91 91 92 93 93 
 
BP, blood pressure. Modified from Task Force on High Blood Pressure in Children and Adolescents (7) 
Shaded area corresponds to reference values of boys 16 years or older in which the reference values for adults are recommended.  
Table 3.1.1. European studies of hypertension prevalence in children and adolescents  
Study Subjects, n Origin Age range and/or 
mean age (yrs) 
Methods Readings, n Prevalence 
Chiolero et al. (31) 5207 Region of 
Switzerland 
12.3 Oscillometric 3 visits to confirm high BP 2.2% 
Katona et al. (32) 10,194 Debrecen, 
Hungary 
15-18, 16.6 Oscillometric  3 visits to confirm high BP 2.5% 
Ostrowska-Nawarycz et 
al. (33) 
25,309 Tódź, Poland 7-18 Auscultatory 
method 
Separate visits to confirm high 
BP 
4.9% 
Akgun et al. (34) 1963 Van, Turkey 7-16 N/A Single visit 9% 
Maldonado et al. (36) 5381 Portugal 4-18, 12.5 Oscillometric  Single visit 13% 
Flechtner-Mors et al. (41) 57,915 
(overweight 
or obese) 
188 centers 
from Germany, 
Austria, and 
Switzerland 
6-18 Oscillometric or 
auscultatory 
method 
Median BP of 6 weeks 22% 
 
 
 
 
 
Table 4.1.2.1. Systolic and diastolic ambulatory blood pressure (systolic/diastolic) values for age (Boys) 
Boys             
Age 24-hr    Day    Night    
 (yr) 50th  75th 90th 95th 50th  75th 90th 95th 50th  75th 90th 95th 
5 105/65 109/69 113/72 116/74 111/72 116/76 120/79 123/81 95/55 99/59 103/62 106/65 
6 106/66 110/69 115/73 118/75 112/72 116/76 121/79 124/81 96/55 100/59 105/63 108/66 
7 106/66 111/70 116/73 119/75 112/73 117/76 122/80 125/82 96/56 101/60 106/64 110/67 
8 107/66 112/70 117/73 120/75 112/73 117/76 122/80 125/82 97/56 102/60 108/64 111/67 
9 108/67 113/70 118/73 121/75 113/72 118/76 123/80 126/82 97/56 103/60 109/64 112/67 
10 109/67 114/70 119/73 123/75 113/72 119/76 124/80 127/82 98/56 104/60 110/64 113/67 
11 110/67 116/71 121/74 12576 115/72 121/76 126/80 129/82 99/56 105/60 111/64 115/67 
12 113/67 118/71 124/74 127/76 117/72 123/76 128/80 132/82 101/56 107/60 113/64 116/67 
13 115/67 121/71 126/74 130/76 120/72 126/76 131/80 135/82 103/56 109/60 115/64 119/67 
14 118/68 124/71 129/75 133/77 122/73 129/77 134/80 138/82 106/57 112/61 118/64 121/67 
15 121/68 127/72 132/75 136/77 125/73 132/77 137/81 141/83 108/57 114/61 120/64 123/66 
16 123/69 129/72 135/76 138/78 128/74 135/78 140/81 144/84 111/57 117/61 123/64 126/66 
The values are in mmHg. Data from (183) 
 
 
 
 
 
 
 
 
 
Table 4.1.2.2. Systolic and diastolic ambulatory blood pressure (systolic/diastolic) values for age (Girls)  
 
Girls             
Age 24-hr    Day    Night    
 (yr) 50th  75th 90th 95th 50th  75th 90th 95th 50th  75th 90th 95th 
5 103/66 108/69 112/72 115/74 108/73 114/77 118/80 121/82 95/56 100/61 105/66 108/69 
6 104/66 109/69 114/72 116/74 110/73 115/77 120/80 122/82 96/56 101/61 106/65 110/68 
7 105/66 110/69 115/72 118/74 111/72 116/77 121/80 123/82 96/56 102/60 107/65 111/67 
8 107/66 112/69 116/72 119/74 112/72 117/76 122/80 124/82 97/55 103/60 108/64 112/67 
9 108/66 113/70 117/73 120/74 112/72 118/76 122/80 125/82 98/55 103/59 109/64 112/67 
10 109/66 114/70 118/73 121/75 113/72 119/76 123/79 126/81 98/55 104/59 110/64 113/67 
11 110/66 115/70 119/73 122/75 114/72 120/76 124/79 127/81 99/54 105/59 110/63 114/66 
12 111/67 116/70 120/74 123/76 115/72 121/76 125/80 128/82 100/54 105/59 110/63 114/66 
13 112/67 117/71 121/74 124/76 116/72 122/77 126/80 129/82 101/54 106/59 111/63 114/66 
14 113/67 118/71 122/74 125/76 118/73 123/77 127/80 130/82 101/55 106/59 111/63 114/65 
15 114/68 118/71 123/75 125/77 119/73 124/77 128/80 130/82 102/55 107/59 111/63 114/65 
16 115/68 119/71 123/75 126/77 120/74 124/77 129/80 131/82 103/55 107/59 111/63 114/65 
The values are in mmHg. Data from (183) 
Table 4.1.2.3.  Systolic and diastolic ambulatory blood pressure (systolic/diastolic) values for height (Boys) 
 Boys            
Height 24-hr    Day    Night    
(cm) 50th  75th 90th 95th 50th  75th 90th 95th 50th  75th 90th 95th 
120 105/66 109/70 114/74 117/77 111/72 116/77 122/80 125/82 94/54 99/58 103/61 106/63 
125 105/66 110/70 115/74 118/77 111/72 117/76 122/80 125/82 95/55 100/58 105/61 108/63 
130 106/66 111/70 116/74 119/77 112/72 117/76 122/80 126/82 96/55 101/59 106/62 110/64 
135 107/66 112/70 117/74 120/77 112/72 117/76 123/80 126/82 97/56 102/59 108/63 111/65 
140 108/67 113/71 118/75 121/77 113/72 118/76 123/80 126/82 98/56 104/60 109/63 113/65 
145 110/67 115/71 120/75 123/77 114/72 119/76 124/79 127/81 99/56 105/60 111/64 114/66 
150 111/67 116/71 121/75 124/77 115/72 120/76 125/79 128/81 100/56 106/60 112/64 116/66 
155 113/67 118/71 123/75 126/77 117/72 122/76 127/79 130/81 101/56 107/60 113/64 117/66 
160 114/67 120/71 124/75 127/77 119/72 124/76 129/79 133/81 103/56 108/60 114/64 118/66 
165 116/68 121/71 126/75 129/78 121/72 126/76 132/80 135/82 104/57 110/60 116/64 119/66 
170 118/68 123/72 128/75 131/78 123/73 128/77 134/80 138/82 106/57 112/61 117/64 121/66 
175 120/68 125/72 130/75 133/78 124/73 130/77 136/81 140/83 107/57 113/61 119/64 122/66 
180 122/68 127/72 131/76 134/78 126/73 132/77 138/81 142/83 109/57 115/61 120/64 124/66 
185 123/68 128/72 133/76 136/78 128/73 134/78 140/81 144/84 110/57 116/61 122/64 125/66 
The values are in mmHg. Data from (183) 
 
 Table 4.1.2.4.  Systolic and diastolic ambulatory blood pressure (systolic/diastolic) values for height (Girls) 
 
Girls             
Height 24-hr    Day    Night    
(cm) 50th  75th 90th 95th 50th  75th 90th 95th 50th  75th 90th 95th 
120 104/66 108/69 112/71 114/72 110/73 114/77 118/80 120/82 95/55 99/60 103/63 106/65 
125 105/66 109/69 113/71 116/73 111/73 115/77 119/80 121/82 96/55 100/60 104/63 107/66 
130 106/66 110/69 114/72 117/73 111/72 116/76 120/80 122/82 96/55 101/59 106/63 108/66 
135 107/66 111/70 115/72 118/74 112/72 116/76 120/80 123/82 97/55 102/59 107/63 109/66 
140 108/66 112/70 116/73 119/75 112/72 117/76 121/80 124/82 98/55 103/59 108/63 110/66 
145 109/66 113/70 117/73 120/75 113/72 118/76 123/80 125/82 98/54 103/59 109/63 112/66 
150 110/67 115/70 119/74 121/76 114/72 119/76 124/80 127/82 99/54 104/59 110/63 113/66 
155 111/67 116/71 120/74 123/76 116/72 121/76 125/80 128/82 100/54 106/59 111/63 114/66 
160 112/67 117/71 121/74 123/76 117/72 122/76 126/80 129/82 101/55 106/59 111/63 114/66 
165 114/67 118/71 122/74 124/76 118/73 123/77 127/80 130/82 102/55 107/59 112/63 114/66 
170 115/68 119/71 123/74 125/76 120/74 124/77 128/80 131/82 103/55 108/61 112/67 115/71 
175 116/69 120/72 124/75 126/76 121/75 125/78 129/81 131/82 105/55 109/59 113/63 115/66 
The values are in mmHg. Data from (183) 
4.1.3.1.Systolic and diastolic home blood pressure values (systolic/diastolic) 
 
Height (cm) 
Percentiles for boys 
 (n=347) 
Percentiles for girls 
(n=420) 
50th 95th 50th 95th 
120 – 129 105/64 119/76 101/64 119/74 
130 – 139 108/64 121/77 103/64 120/76 
140 – 149 110/65 125/77 105/65 122/77 
150 – 159 112/65 126/78 108/66 123/77 
160 – 169 115/65 128/78 110/66 124/78 
170 – 179 117/66 132/78 112/66 125/79 
180 – 189 121/67 134/79 114/67 128/80 
The values are in mmHg. Data from (64) 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2.1.  Family and clinical history 
Family History 
 Hypertension 
 Diabetes 
 Dyslipidemia 
 Cardiovascular disease 
 Hereditary renal disease (Polycystic kidney disease, Alport syndrome) 
 Hereditary endocrine disease (Adrenal tumors, glucocorticoid-remediable 
aldosteronism, multiple endocrine neoplasia type 2, monogenic syndromes of 
hypertension) 
 Syndromes associated with hypertension (Neurofibromatosis) 
Clinical History 
1. History or symptoms of secondary hypertension  
a) Perinatal history: oligohydramnios, anoxia, umbilical artery catheterization, 
renal artery/vein thrombosis  
b) Underlying or concurrent diseases: 
 Renal or urologic disease, trauma, recurrent urinary tract infections, edema, 
weight loss, failure to thrive, thirst/polyuria, nocturia, hematuria 
 Cardiac, endocrine, or neurological disease, cold extremities, intermittent 
claudication, palpitations, sweating, fever, pallor, flushing, muscle weakness, 
crumbs, virilization, primary amenorrhea, male pseudo- hermaphroditism, 
skin abnormalities 
 Systemic disease (lupus erythematosus) 
c) Drug/substance intake: steroids, calcineurin inhibitors, tricyclic anti-
depressants, decongestants, oral contraceptives, amphetamines, cocaine 
2. History or symptoms of target organ damage  
 Headache, epistaxis, vertigo, visual impairment, facial palsy, seizures, strokes, 
low school performance, dyspnea, chest pain, palpitations, syncope 
3. Risk factors 
 Diabetes mellitus 
 Dyslipidemia 
 Obesity, growth patterns 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Physical exercise, dietary habits 
 Smoking, alcohol 
 Birth weight, gestational age 
 Snoring, sleep apnea history 
4. Hypertension onset and management 
 Age at presentation 
 Previous BP measurements 
 Past and current treatment 
 Compliance-adverse effects 
Table 4.4.1.  Physical examination  
Organ system / finding Causative factor for hypertension Sequelae of hypertension 
General Poor growth, pallor; CKD 
Oedema 
Obesity 
Cushingoid features 
Features of Turner, William, 
Marfan, Klippel-Trenaunay-Weber, 
Feuerstein-Mims, von Hippel-
Lindau, multiple endocrine 
neoplasia syndromes 
 
Skin Rash; SLE, vasculitis 
Neurofibromas, axillary freckling 
Acanthosis nigricans 
Pseudoxanthoma elasticum 
Congenital adrenal hyperplasia 
 
Eye Cataract; corticosteroids 
Haemangioblastoma; von Hippel-
Lindau 
Proptosis; hyperthyroidism 
Hypertensive retinopathy 
Abdomen Mass; Wilms tumour, 
neuroblastoma, 
phaeochromocytoma, recessive or 
dominant polycystic kidney disease, 
multicystic dysplastic kidney, 
obstructive uropathy, acute renal 
venous thrombosis 
Hepatosplenomegaly; recessive 
polycystic kidney disease 
 
Neurological  Cranial nerve palsy 
(particularly IIIrd and VIth 
cranial nerves) 
Hemiparesis / other evidence 
of stroke 
Cardiovascular Cardiac murmur (coarctation, aortic 
stenosis) 
Bruit over flanks (renal artery), 
abdomen, back, neck, head 
Weak femoral pulses, interscapular 
bruit (coarctation, mid-aortic 
syndrome) 
Tachycardia (phaeochromocytoma) 
Left ventricular enlargement 
Left ventricular failure 
Genitalia Virilisation (congenital adrenal 
hyperplasia) 
 
CKD (Chronic kidney disease); (SLE) Systemic lupus erythematosus 
 
 
 
Table 4.5.1.  Laboratory investigation and imaging studies  
Laboratory tests  
 
Comments 
Routine laboratory tests to be performed in all 
children with hypertension 
 
  
Plasma creatinine, urea, electrolytes, uric acid  
Fasting plasma glucose  
Plasma cholesterol (total, HDL, LDL) and triglycerides   
Urinalysis and culture  Microscopy for red cell casts indicative 
of glomerular disease; white cell casts 
indicative of interstitial disease 
Quantification of albuminuria (albumin:creatinine 
ratio) proteinuria (protein:creatinine ratio) 
 
Echocardiography 
Renal ultrasonography 
 
Additional laboratory tests in specific circumstances 
 
  
Plasma renin activity (PRA) and aldosterone Renovascular hypertension (high PRA), 
primary hyperaldosteronism (PRA is 
very low in mineralocorticoid-related 
diseases and there may be associated 
hypokalaemia)  
  
Urine and plasma catecholamines or metanephrines Pheocromocytoma, extra-adrenal 
chatecolamine producing tumours 
  
Urinary free cortisol Cushing syndrome 
Urinary steroid profiles and more complex endocrine 
investigations 
 
Plasma cortisol, ACTH, 24h urinary free cortisol  
  
Molecular genetic studies e.g. apparent 
mineralocorticoid excess*, Liddle syndrome*, 
glucocorticoid-remediable aldosteronism*, 
hypertensive forms of congenital adrenal hyperplasia 
(11β-hydroxylase deficiency, 17α-hydroxylase 
deficiency, neurofibromatosis, von Hippel-Lindau , 
multiple endocrine neoplasia syndromes 
*Monogenic causes of hypertension 
(suspect where low renin 
hypertension and family history of 
early onset severe hypertension / 
death from cerebrovascular events 
and refractory hypertension) 
  
Thyroid function tests: FT4, TSH Thyrotoxicosis 
  
Plasma deoxycorticosterone and corticosterone, 18-
hydroxycorticosterone, 18-hydroxy 
deoxycorticosterone, 11 deoxycortisol 
Congenital adrenal hyperplasia 
  
Drug levels Identify drugs that may cause 
hypertension e.g. amphetamines, 
ecstasy 
(PRA) Plasma renin activity; (HDL) high density lipoprotein; (LDL) low density lipoprotein; 
(ACTH) adrenocorticotropic hormone; (FT4) thyroxine; (TSH) Thyroid-stimulating hormone 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(LVMI) left ventricular mass index; (RWT) relative wall thickness; (cIMT) carotid intima media 
thickness; (PWV) Pulse wave velocity 
 
 
 
 
 
 
 
 
4.7.1. Criteria to define hypertension-induced organ damage 
 
Left ventricular hypertrophy 
Left ventricular hypertrophy should be defined as LVMI or relative wall thickness (RWT) ≥ 
95th percentile by age and gender (107,108,109). 
 
Carotid intima thickness 
cIMT  ≥ 95th percentile by age and gender (113,114) 
 
Pulse wave velocity 
PWV  ≥ 95th percentile by age and gender (84,123,124) 
 
Kidney 
Albuminuria (as measured by urinary albumin/creatinine quotient >30mg/g creatinine or 
>3mg/mmol creatinine) or even proteinuria (as measured by urinary albumin/creatinine 
quotient (>300mg/g creatinine or >30mg/mmol creatinine) or by 24 h urinary protein 
excretion (>200 mg/m²/day) (1) 
 
Table 7.2.1.  Blood pressure goal in hypertensive children (for office, home and 24-hour 
ambulatory blood pressure measurements). 
 
General hypertensive populationa 
 Blood pressure goal   < 95th pct is recommended 
     < 90th pct should be considered 
Diabetes type 1 and type 2b 
             Blood pressure goal  < 90th pct is recommended 
     < 75th pct is recommended in children with non-proteinuric CKD  
                                                                       < 50th pct is recommended in children with proteinuric CKD 
Children with CKDc 
            Blood pressure goal  < 75th pct is recommended in children with non-proteinuric CKD 
     < 50th pct is recommended in children with proteinuric  CKD 
 
a In subjects aged 16 year or older, the adult cut-off values for office BP are used, 140/90 mmHg;  
b  In subjects aged 16 year or older, the adult cut-off values for office BP are used, 130/80 mmHg or 125/75 
mmHg with proteinuric CKD;  
c In subjects aged 16 year or older, the adult cut-off values for office BP are used, 130/80 mmHg or 125/75 
mmHg with proteinuric CKD 
(CKD) Chronic kidney disease 
 
 
 
 
 
  
 
 
 
 Table 8.2.1.  Antihypertensive medications for use in children and young adults 
Class of drug Drug Recommended 
starting dose 
(per day) 
Maximal dose 
(per day) 
Dosing interval 
Diuretics Amiloride 0.4-0.6mg/kg 20mg Daily 
 Chlortalidone 0.3mg/kg 2mg/kg up to 
50mg 
Daily 
 Furosemide 0.5-2mg/kg 6mg/kg Daily – Twice daily 
 Hydrochlorothiazide 0.5-1mg/kg 3mg/kg/day  Daily 
 Spironolactone 1mg/kg 3.3mg/kg up to 
100mg 
Daily – Twice daily 
 Eplerenone 25mg 100mg Daily – Twice daily 
 Triamterene 1-2mg/kg 3-4mg/kg up to 
300mg 
Twice daily 
Beta blockers Atenolol 0.5-1mg/kg 2mg/kg up to 
100mg 
Daily – Twice daily 
 Metoprolol 0.5-1mg/kg 2mg/kg Daily – Twice daily 
 Propranolol 1mg/kg 4mg/kg up to 
640mg 
Twice-Three times 
daily 
Calcium channel 
blockers 
Amlodipine 0.06-0.3mg/kg 5-10mg Daily 
 Felodipine 2.5mg 10mg Daily 
 Nifedipine (extended 
release form) 
0.25-0.5mg/kg 3mg/kg up to 
120mg 
Daily – Twice daily 
ACE inhibitors Benazepril 0.2mg/kg up to 
10mg 
0.6mg/kg up to 
40mg 
Daily 
 Captopril 0.3-0.5mg/kg 
PER DOSE 
6mg/kg Twice – Three 
times daily 
 Enalapril 0.08-0.6mg/kg  Daily 
 Fosinopril 0.1-0.6mg/kg 40mg Daily 
 Lisinopril 0.08-0.6mg/kg 0.6mg/kg up to 
40mg 
Daily 
 Ramipril 1.5-6mg/  Daily 
ARBs Candesartan 0.16-0.5mg/kg  Daily 
 Irbesartan 75-150mg 300mg Daily 
 Losartan 0.7mg/kg up to 
50mg 
1.4mg/kg up to 
100mg 
Daily– Twice daily 
 Valsartan 0.4mg/kg 40-80mg Daily 
Alpha and beta 
blocker 
Labetolol 1-3mg/kg 10-12mg/kg up to 
1200mg 
Twice daily 
Central alpha-
agonist 
Clonidine 0.2mg/kg 2.4mg Twice daily 
Peripheral alpha-
blockers 
Doxazosin 1mg 4mg Daily 
 Prazosin 0.05-0.1mg/kg 0.5mg/kg Three times daily 
Vasodilators Hydralazine 0.75mg/kg 7.5mg/kg up to 
200mg 
Four times daily 
 Minoxidil 0.2mg/kg 50-100mg/day Daily to three 
times daily 
 
 Table 8.2.2. Clinical conditions for which specific antihypertensive drug classes are recommended or contraindicated 
 
Antihypertensive class Recommended Contraindicated 
Diuretics potassium-sparing Hyperaldosteronism Chronic renal failure (*) 
Competitive athletes 
Thiazide and thiazide-like diuretics Chronic renal failure 
Corticosteroid-induced HTN 
Competitive athletes 
Diabetes 
Diuretics Loop-acting Congestive heart failure  
Beta-adrenergic blockers Coarctation of aorta 
Congestive heart failure 
Migraine 
Bronchial asthma (*) 
Diabetes 
Competitive athletes 
Psoriasis 
Calcium channel blockers Posttransplantation 
Migraine 
Coarctation of aorta 
Congestive heart failure 
Angiotensin-converting enzyme inhibitors Chronic kidney disease 
Diabetes mellitus 
Microalbuminuria 
Congestive heart failure 
Obesity-linked primary HTN 
Bilateral renal artery stenosis (*) 
Renal artery stenosis in solitary kidney (*) 
Hyperkalemia (*) 
Pregnancy (*) 
Females of child-bearing potential should use 
reliable contraception 
Angiotensin-receptor blockers Chronic kidney disease 
Diabetes mellitus 
Microalbuminuria 
Congestive heart failure 
Obesity-linked primary HTN 
Bilateral renal artery stenosis (*) 
Renal artery stenosis in solitary kidney (*) 
Hyperkalemia (*) 
Pregnancy (*) 
Intravenous vasodilators Life-threatening conditions  
(*) absolute contraindication 
 
Table 8.2.3. Presenting features and appropriate therapies for monogenic hypertension 
Disorder Inheritance Gene Presentation Potassium Renin Aldosterone Treatment 
Apparent 
mineralocorticoid 
excess 
AR 
HSD11b2 
All ages Low/N Low Low Spironolactone, 
eplerenone, 
amiloride 
Glucocorticoid 
remediable 
aldosteronism 
AD 
CYP11B2/ 
CYP11B1 
Infant / Child Low/N Low Low/N Amiloride, 
triamterene, 
dexamethasone 
Congenital 
adrenal 
hyperplasia 
AR 
CYP21A2 
CYP11B1 
Infant Low/N Low Low Spironolactone, 
eplerenone 
dexamethasone 
Liddle syndrome AD SCNN1B, 
SCNN1G 
Child/Adult Low/N Low Low Amiloride. 
triamterene 
Gordon 
syndrome 
AD KLHL3, 
CUL3, 
WNK1, 
WNK4 
Adult/Child High/N Low High/N Thiazide 
AR, autosomal recessive; AD, autosomal dominant  
HSD11b2, 11b hydroxysteroid dehydrogenase type 2 enzyme (11beta-HSD2) gene 
CYP11B1, Steroid 11β-hydroxylase deficiency (11β-OHD) gene  
CYP11B2, Aldosterone synthase gene 
CYP21A2, Steroid 20β-hydroxylase deficiency (11β-OHD) gene 
SCNN1G and SCNN1B, Subunits of ENaC genes 
KLHL3, Kelch-like 3 gene 
CUL3, Cullin3 gene 
WNK1 or 4, With-no-lysine kinase 1 and 4 
 
Table 9.6.1. Antihypertensive drugs for hypertensive emergencies and urgencies 
Drug  Class Route  Dose Onset of action Comment 
 
Sodium 
nitroprusside 
Direct vasodilator  Intravenous 
infusion 
0.5-8             
μg/kg  per min  
Within seconds May cause 
thiocyanate toxicity, 
inactivated by light  
Nitroglycerine 
 
Direct vasodilator Intravenous   
infusion  
0.1-2             
μg/kg per min  
1-2 minutes  May cause 
methemoglobinemiia, 
vasodilating effect 
primarily on the 
venous side – 
efficient in heart 
failure, limited 
efficacy in children 
Labetalol Alpha and beta 
blocker  
Intravenous 
infusion 
0.25-3          
mg/kg per hour  
5-10 min.  Contraindication in 
asthma,  heart 
failure,  may cause 
bradycardia 
Nicardipine Calcium channel 
blocker 
Intravenous  
infusion 
1-3                 
μg/kg per min 
Within minutes  Reflex tachycardia 
Clonidine Central alpha- 
agonist  
Intravenous  
bolus  
2-6  
μg/kg per dosis 
10 min.  Dry mouth, sedation, 
rebound 
hypertension 
Esmolol Beta-blocker Intravenous  
infusion 
100-500 
μg/kg/min  
within seconds Contraindication in 
asthma, may cause 
bradycardia 
Enalaprilat ACEI Intravenous 
bolus 
0.005-0.01 
mg/kg per dosis 
15 min.  Contraindication in 
suspected bilateral 
renal artery stenosis 
Furosemide Loop diuretic Intravenous 
bolus 
0.5-5 
mg/kg per dosis 
within minutes Hypokalemia. Useful 
in volume 
hypertension 
Urapidil  
 
 
Peripheral alpha 
blocker and central 
agonist of 5-HT1A 
receptors  
Intravenous 
infusion  
initial dose: 0.5-
4.0        mg/kg 
per hour 
maintenance 
dose:  
0.2-2.0  
mg/kg per hour 
1-5 minutes  May cause sedation,  
palpitation, nausea 
Nifedipine Calcium channel 
blocker 
Orally  0.25  
mg/kg per dosis 
20-30 min.  May cause 
unpredictable 
hypotension, reflex 
tachycardia 
Isradipine 
  
Calcium channel 
blocker (L-type) 
Orally  0.05-0.1  
mg/kg per dosis 
1 hour  higher doses may 
cause BP drop of 
>25%  
Captopril ACEI Orally 0.1-0.2         
mg/kg per dosis 
10-20 min.  Contraindication in 
suspected bilateral 
renal artery stenosis 
Minoxidil Direct vasodilator Orally 0.1-0.2 
mg/kg per dosis 
5-10 min.  Fluid retention 
 
Table 11.9.1. Drug-induced hypertension  
Drug/substance Mechanism of action Treatment 
Glicocorticoids Sodium retention, RAAS 
activation, sympathetic 
system activation 
Decrease dose if possible, 
diuretics, ACEi/ARB, DCCB 
Cyclosporine Arteriolar constriction, 
sodium retention 
DCCB, ACEi/ARB; switch to 
tacrolimus 
Tacrolimus Less potent hypertensive 
effect than Cyclosporine 
DCCB 
Liquorice Mineralocorticoid effect 
caused by inhibition of 
11beta dehydrogenase 
isoform 2  
Avoid; mineralocortiocid 
receptor antagonists 
Non-steroidal antinflammatory 
drugs; cyclloxigenase 2 
inhibitors 
Sodium retention 
(indomethacin is most 
potent) 
Sodium restriction, diuretics, 
DCCB 
Antidepressants and 
antipsychotics (velafaxine, 
desvenlafaxine, tricyclic 
antidepressants, clozapine) 
Inhibition of serotonin and 
norepinephrine reuptake 
 
Monoamine oxidase inhibitors Sympathomimetic effect Avoidance of tyramine-rich 
foods; chlorpromazine 
Oral contraceptives containing 
estrogens and progesterone 
Mineralocorticoid effect , 
increased synheosis of 
angiotensinogen 
Diuretics, ACEi/ARB 
Androgens Mechanism not know. 
Probable mineralocorticoid 
effect. 
Diuretics, ACEi/ARB, DCCB 
Phenylephrine hydrochloride 
(used as upper respiratory tract 
decongestant and as opthalmic 
drops in neonates/infants) 
Sympathomimetic effect Beta and alpha-adrenolytics 
Pseudoephedrine 
hydrochloride 
Sympathomimetic effect Alpha-adrenolytics 
Ketamine hydrochloride Sympathomimetic effect   alpha-adrenolytics, DCCB; 
propohol attenuates 
sympathomimetic effect 
Methylphenidate, 
amphetamine 
Sympathomimetic effects Not known – beta and alpha-
adrenolytics proposed 
Anti-VEGF pathway drugs Increase of peripheral 
vascular resistance 
DCCB, ACEi/ARB 
Erythropoetin/erythtropoesis 
stimulating agents 
Increase of peripheral 
vascular resistance 
DCCB, lower hemoglobin 
target 
Caffeine Sympathomimethic effects Beta-adrenolytics 
Cocaine, amphetamine, 
modafenil 
Sympathomimetic effect Benzodiazepines; avoid 
beta-adrenolytics 
Ephedra alkaloids, synephrine, 
octopamine 
Sympathomimetic effect Avoid 
(ACEi)  Angiotensine converting enzyme inhibitors; (ARB) Angiotensine II receptor blocker; 
(DCCB) dihydropyridine calcium channel blockers; VEGF vascular endothelial growth factor; 
RAAS, renin-angiotensin-aldosterone system 
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